WO2025129290A1

WO2025129290A1 - Methods for treating keratin fibers in a dyeing process

Info

Publication number: WO2025129290A1
Application number: PCT/BR2023/050479
Authority: WO
Inventors: Pedro Henrique CARVALHO; Beatriz TAVARES FERREIRA; Manon Chaumontet
Original assignee: LOreal SA
Current assignee: LOreal SA
Priority date: 2023-12-20
Filing date: 2023-12-20
Publication date: 2025-06-26
Anticipated expiration: 2026-06-20
Also published as: FR3157164A3

Abstract

The disclosure relates to methods for treating keratin fibers. The methods comprise treating the keratin fibers with treatment compositions in connection with a hair dyeing process, the treatment compositions comprising (a) at least one amino acid, (b) at least one osmolyte, (c) at least one carboxylic acid, and (d) at least one solvent.

Description

METHODS FOR TREATING KERATIN FIBERS IN A DYEING PROCESS

TECHNICAL FIELD

The present disclosure relates to methods for treating keratin fibers, such as hair, for example for repairing damaged keratin fibers, providing strength to keratin fibers, and/or for reducing elasticity of keratin fibers, in connection with a process for dyeing the keratin fibers.

BACKGROUND

Consumers use cosmetic compositions and processes to change or enhance the appearance of their hair, e.g., by changing the color, style, and/or shape of the hair, and/or by imparting various properties to hair, such as shine and conditioning. However, many compositions and processes for changing the appearance of the hair, such as compositions and processes for permanently altering the color of the hair, involve harsh chemical treatments. For example, compositions and processes for altering the color of the hair generally require the presence of harsh chemical compounds such as oxidizing agents. In order to alter the color of the hair, these components must first break down the natural components in the hair fibers.

It is known that, while such processes effectively alter the color of the hair, the chemical agents used inherently result in hair damage, and negatively impact the strength, elasticity, and porosity of the hair fibers. For example, hair that has been bleached, dyed, repeatedly styled, etc., is often dry, frizzy, and generally unhealthy in feel and appearance. Additionally, the damaged hair is brittle and/or has increased elasticity, which result in greater incidence of hair breakage. As such, consumers seek compositions and processes for preventing or minimizing such damage and/or for repairing hair that has been damaged by these treatments and processes. In particular, consumers desire hair that is strong, does not break easily, is able to be stretched or manipulated while retaining the ability to return to its original state without breakage (i.e. has decreased elasticity), and that feels soft and healthy to the touch and also appears shiny and healthy.

However, formulating compositions that satisfactorily address these issues has proven to be challenging. For example, some compositions that attempt to address the problem simply coat the hair with compounds that can improve the feel and appearance of the hair; however, this approach is only temporary and superficial. Instead of preventing or repairing hair damage, this approach simply masks the damage until the hair is next rinsed or washed. Other compositions attempt to address the damage within the hair fiber, but to date have not been satisfactory.

The present inventors have now discovered a synergistic combination of components that is surprisingly effective for preventing or minimizing hair damage and treating damaged hair. Hair treated with compositions according to the disclosure exhibit surprisingly reduced signs of damage including greater strength and/or decreased elasticity, in particular hair that has been damaged by harsh chemical treatments such as dyeing.

SUMMARY

The present disclosure relates to methods for treating keratin fibers, e.g. human hair, for example for preventing, minimizing, and/or repairing hair damage such as damage caused by hair dyeing compositions and processes. The compositions which can be used in methods according to the disclosure (“treatment compositions”) comprise a synergistic combination of one or more amino acids, one or more osmolytes, and one or more carboxylic acids, and the methods comprise applying a treatment composition according to the disclosure to the keratin fibers in connection with a hair dyeing process.

In various embodiments, the hair treatment compositions that can be used in methods according to the disclosure comprise (a) at least one amino acid, (b) at least one osmolyte, (c) at least one carboxylic acid, and (d) optionally at least one solvent. The pH of the treatment compositions is generally less than 7 or less than about 6, for example ranging from about 2 to about 5, or from about 3 to about 4.

In some embodiments the treatment compositions that can be used in methods according to the disclosure comprise at least one amino acid chosen from basic amino acids, for example arginine, histidine, lysine, salts thereof, or combinations thereof. In various embodiments, the total amount of basic amino acids and salts thereof ranges from about 0.1 % to about 15%, preferably from about 1 % to about 12%, more preferably from about 2% to about 10%, more preferably still from about 3% to about 7%, and most preferably from about 4% to about 6% by weight, relative to the total weight of the composition. In further embodiments the compositions comprise at least one amino acid chosen from acidic or neutral amino acids and salts thereof, for example serine. In various embodiments, the total amount of acidic and/or neutral amino acids and salts thereof ranges from about 0.01 % to about 5%, preferably from about 0.05% to about 4%, more preferably from about 0.1 % to about 3%, and most preferably from about 0.25% to about 2.5% by weight, relative to the total weight of the composition. In still further embodiments, the compositions comprise a mixture of basic, acidic, and/or neutral amino acids, for example the compositions may comprise arginine and serine. In various embodiments, the total amount of amino acids and salts thereof present in the composition ranges from about 0.1 % to about 15%, preferably from about 1 % to about 12%, more preferably from about 2% to about 10%, more preferably still from about 3% to about 7%, and most preferably from about 4% to about 6% by weight, relative to the total weight of the composition.

In some preferred embodiments, compositions that can be used in the methods comprise one or more amino acids chosen from glycine, proline, methionine, serine, arginine, lysine, histidine, salts of any of the foregoing (in particular alkali metal, alkaline earth metal, or zinc salts), and combinations of two or more thereof.

In various embodiments, the treatment compositions comprise at least one osmolyte chosen from carbohydrate sugars, methylsulfonium compounds, polyamines, and/or amino acid derivatives such as betaines, preferably chosen from compounds of formula (II). In various embodiments, the total amount of osmolytes present in the treatment composition ranges from about 0.01 % to about 10%, preferably from about 1 % to about 5%, more preferably from about 1 .25% to about 4%, more preferably still from about 1 .5% to about 3%, and most preferably from about 2% to about 2.5% by weight, relative to the total weight of the composition. In various embodiments, the treatment composition has a weight ratio of the total amount of amino acids to the total amount of osmolytes that is equal to or greater than about 0.5, such as greater than about 1 , preferably ranging from about 1 .25 to about 3.5, more preferably from about 1 .5 to about 3, more preferably still from about 1 .75 to about 2.5, and most preferably from about 1 .75 to about 2.25.

In various embodiments, the at least one carboxylic acid is chosen from oxalic acid, malonic acid, glutaric acid, succinic acid, adipic acid, glycolic acid, citric acid, tartaric acid, malic acid, maleic acid, lactic acid, salts thereof, or combinations of two or more thereof, and preferably citric acid, lactic acid, salts thereof, or combinations of two or more thereof. In various embodiments, the total amount of carboxylic acids and salts thereof may range from about 0.5% to about 20%, preferably from about 1 % to about 15%, more preferably from about 2% to about 12%, more preferably still from about 3% to about 10%, and most preferably from about 4% to about 7% by weight, relative to the total weight of the composition. In various embodiments, the treatment composition has a weight ratio of the total amount of amino acids and salts thereof to the total amount of carboxylic acids and salts thereof of greater than about 0.5, such as greater than about 0.7, preferably ranging from about 0.75 to about 2, and more preferably from about 0.8 to about 1 .5.

The solvent may comprise water and/or at least one non-aqueous solvent, and in some embodiments comprises water and at least one non-aqueous solvent. Optionally, the treatment compositions comprise water and at least one nonaqueous solvent, preferably chosen from polyols, and have a total amount of nonaqueous solvents ranging from about 1 % to about 20%, preferably from about 5% to about 20%, more preferably from about 5% to about 15%, and most preferably from about 8% to about 12% by weight, relative to the total weight of the composition.

The treatment compositions that can be used in the methods according to the disclosure may optionally also include at least one additional component chosen from fatty compounds, surfactants, thickening agents, or combinations or two or more thereof.

In certain embodiments, treatment compositions that can be used in methods according to the disclosure comprise (a) at least one amino acid and/or a salt thereof, (b) at least one betaine, preferably at least one compound of formula (II), for example glycine betaine, in an amount ranging from about 1% to about 5% by weight, relative to the total weight of the composition, (c) at least one carboxylic acid and/or a salt thereof, (d) at least one solvent, and (e) optionally at least one additional component chosen from fatty compounds, surfactants, thickening agents, or combinations thereof. For example, in at least some embodiments, the treatment composition comprises arginine and the total amount of amino acids ranges from about 1 % to about 10% by weight, relative to the total weight of the composition, and wherein the total amount of carboxylic acids ranges from about 0.5% to about 20% by weight, relative to the total weight of the composition. The pH of the treatment compositions is generally less than 7, for example ranging from about 2 to about 5, or from about 3 to about 4. In various embodiments, the total amount of non-aqueous solvents ranges from about 1% to about 20%, preferably from about 2% to about 18%, more preferably from about 3% to about 15%, and most preferably from about 4% to about 12% by weight, relative to the total weight of the composition. In some embodiments, the treatment composition has a weight ratio of the total amount of amino acids and salts thereof, for example arginine, serine, salts thereof, or combinations thereof, to the total amount of betaines, preferably chosen from compounds of formula (II) and salts thereof, for example glycine betaine, that is greater than or equal to about 0.5, such as greater than about 1 , preferably from about 1 .25 to about 3.5, more preferably from about 1.5 to about 3, more preferably still from about 1.75 to about 2.5, and most preferably from about 1.75 to about 2.25. In some embodiments, the treatment composition has a weight ratio of the total amount of amino acids and salts thereof to the total amount of carboxylic acids and salts thereof that is greater than about 0.5 or greater than about 0.7, preferably ranging from about 0.75 to about 2, and more preferably from about 0.8 to about 1 .5.

In preferred embodiments, the treatment compositions comprise (a) at least one amino carboxylic acid or a salt thereof, preferably chosen from arginine and/or a salt thereof, (b) at least one betaine derivative, preferably chosen from glycine betaine, (c) at least one carboxylic acid, preferably chosen from citric acid, lactic acid, and/or salts thereof, and (d) water. For example, the composition may comprise (a) from about 2% to about 6% of arginine and/or a salt thereof, (b) from about 0.5% to about 3.5% of glycine betaine, (c) at least one carboxylic acid, preferably chosen from citric acid, lactic acid, and/or salts thereof, (d) water and at least one non-aqueous solvent, and (e) optionally serine, wherein the total amount of carboxylic acids and salts thereof ranges from about 2% to about 10%, and wherein all amounts are by weight, relative to the total weight of the composition. The pH of the treatment compositions is generally less than 7, for example ranging from about 2 to about 5, or from about 3 to about 4. In various embodiments, the total amount of non-aqueous solvents ranges from about 1 % to about 20%, preferably from about 2% to about 18%, more preferably from about 3% to about 15%, and most preferably from about 4% to about 12% by weight, relative to the total weight of the composition. In some embodiments, the treatment composition has a weight ratio of the total amount of amino acids and salts thereof to glycine betaine of greater than about 0.5, such as greater than about 1 , preferably from about 1 .25 to about 3.5, more preferably from about 1.5 to about 3, more preferably still from about 1.75 to about 2.5, and most preferably from about 1.75 to about 2.25. In some embodiments, the treatment composition has a weight ratio of the total amount of amino acids and salts thereof to the total amount of carboxylic acids and salts thereof of greater than about 0.5, such as greater than about 0.7, preferably ranging from about 0.75 to about 2, more preferably from about 0.8 to about 1.5. In some embodiments, the compositions include at least one additional component chosen from fatty compounds, surfactants, thickening agents, or combinations thereof. If present, the compositions comprise serine in an amount ranging from about 0.01 % to about 2%, preferably from about 0.05% to about 1.5%, more preferably from about 0.05% to about 1 %, and most preferably from about 0.05% to about 0.5% by weight, relative to the total weight of the composition. When the compositions comprise serine, the compositions may optionally have a weight ratio of the total amount of amino acids to serine of greater than about 2, preferably ranging from about 2 to about 15, more preferably from about 4 to about 14, more preferably still from about 6 to about 13, and most preferably from about 8 to about 12. When the compositions comprise serine, the compositions may optionally have a weight ratio of glycine betaine to serine of greater than about 2, preferably ranging from about 2 to about 10, more preferably from about 3 to about 8, more preferably still from about 3.5 to about 7, and most preferably from about 4 to about 6.

The methods comprise applying a treatment composition according to the disclosure to keratin fibers in connection with a hair dyeing process. In various embodiments, the methods comprise applying a treatment composition to hair before and/or after a dyeing composition is applied to the hair, with or without rinsing between application of the treatment composition and dyeing composition. The treatment composition may also be applied to hair simultaneously with a dyeing composition, for example by mixing the treatment composition and dyeing composition before the mixture is applied to the hair, or by applying the treatment composition and dyeing composition separately to the hair at the same time. The dyeing compositions that are used according to the disclosure are not limited, and can be those that are typically used to dye hair, for example oxidative dye compositions comprising oxidizing agents and oxidative dye compounds.

BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1A-1 B show the structures of certain exemplary osmolytes that can be included in compositions according to the disclosure.

DETAILED DESCRIPTION

The disclosure relates to methods for treating keratin fibers, such as hair, for example for repairing damaged keratin fibers, providing strength to keratin fibers, and/or reducing elasticity of keratin fibers in connection with a process for dyeing the keratin fibers.

I. TREATMENT COMPOSITIONS The treatment compositions comprise (a) at least one amino acid, (b) at least one osmolyte, (c) at least one carboxylic acid, and (d) optionally at least one solvent. The treatment compositions may optionally comprise one or more additional components.

Amino Acids

Treatment compositions that can be used in methods according to the disclosure comprise at least one amino acid. Optionally, in various embodiments, treatment compositions according to the disclosure can comprise one, two, or three amino acids, or more. Amino acids that can be chosen include those that are basic, acidic, or neutral at neutral pH. In preferred embodiments, compositions include at least one basic amino acid.

As used herein, the term “amino acid” includes amino carboxylic acids and salts thereof as well as amino sulfonic acids and salts thereof. As used herein, amino acids are understood to refer to organic compounds containing a carboxylic acid group

( — COOH) (amino carboxylic acids) and/or sulfonic acid group ( — S(=O)2-OH) (amino sulfonic acids) and an amino group ( — NH2) which may be primary or secondary, or may be intra-cyclic, along with a side chain (R group) specific to each amino acid.

Amino carboxylic acids that may be chosen include, for example, alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and combinations of two or more thereof. Exemplary amino sulfonic acids include aminomethane sulfonic acid, 2-aminoethane sulfonic acid (taurine), aminopropane sulfonic acid, aminobutane sulfonic acid, aminohexane sulfonic acid, aminoisopropyl sulfonic acid, aminododecyl sulfonic acid, aminobenzene sulfonic acid, aminotoluene sulfonic acid, sulfanilic acid, chlorosu Ifani lie acid, diamino benzene sulfonic acid, amino phenol sulfonic acid, amino propyl benzene sulfonic acid, amino hexyl benzene sulfonic acid, and combinations of two or more thereof.

Salts of amino acids are also included in the term “amino acid,” whether or not so stated. By way of non-limiting example, salts that may be chosen include salts with organic or mineral bases, for example the salts of alkali metals, such as the lithium, sodium, or potassium salts; the salts of alkaline earth metals, such as the magnesium or calcium salts, and the zinc salts. Furthermore, amino acids can be in either the D-, L-, or DL- configuration. In some preferred embodiments, it is advantageous to choose amino acids in the L- configuration, for example L-proline, L-methionine, L-serine, L-arginine, L-lysine, or combinations of two or more thereof.

In some embodiments it is particularly advantageous to choose one or more amino carboxylic acids. Thus, in various embodiments, treatment compositions according to the disclosure comprise one or more amino acids of formula (I):

(I) wherein: p is an integer equal to 1 or 2, and when p = 1 , R forms, together with the nitrogen atom, a saturated heterocycle comprising from 5 to 8 ring members, preferably 5 ring members, it being possible for this ring to be substituted by one or more groups chosen from hydroxyl or (C1 -C4)alkyl; or when p = 2, R represents a hydrogen atom or a saturated, linear, or branched (C1 -C12)alkyl group, preferably a (C1 -C4)alkyl group, optionally interrupted by one or more heteroatoms or groups chosen from -S-, -NH-, or - C(NH)-, and/or optionally substituted by one or more groups chosen from hydroxyl (- OH), amino (-NH₂), -SH, -COOH,

-CONH2, — N H— C(N H)— N H2, or an imidazole ring.

In some embodiments when p = 1 , R forms, together with the nitrogen atom, a saturated heterocycle comprising 5 ring members, this ring not being substituted.

In some embodiments when p = 2, R represents a hydrogen atom or a saturated, linear, or branched (C1 -C4)alkyl group, optionally substituted by one or more groups chosen from hydroxyl (-OH), amino (-NH2), -CONH2, -NH-C(NH)-NH2, or an imidazole ring. In some embodiments p is preferably 2.

In some embodiments, the treatment compositions comprise one or more amino acids chosen from glycine, proline, methionine, serine, arginine, lysine, histidine, salts of any of the foregoing (in particular alkali metal, alkaline earth metal, or zinc salts), or combinations of two or more thereof. In at least certain embodiments, the amino acid compounds in the composition consist essentially of or consist of amino acids chosen from glycine, proline, methionine, serine, arginine, lysine, histidine, salts of any of the foregoing (in particular alkali metal, alkaline earth metal, or zinc salts), or combinations of two or more thereof.

In some embodiments, the amino acid(s) useful in the treatment compositions may comprise, consist essentially of, or consist of glycine and/or salts thereof. In other embodiments, the amino acid(s) useful in the treatment compositions may comprise, consist essentially of, or consist of arginine and/or salts thereof. In other embodiments, the amino acid(s) useful in the treatment compositions may comprise, consist essentially of, or consist of proline and/or salts thereof. In still other embodiments, the amino acid(s) useful in the treatment compositions may comprise, consist essentially of, or consist of methionine and/or salts thereof. In other embodiments, the amino acid(s) useful in the treatment compositions may comprise, consist essentially of, or consist of serine and/or salts thereof. In still other embodiments, the amino acid(s) useful in the treatment compositions may comprise, consist essentially of, or consist of arginine and/or salts thereof. In other embodiments, the amino acid(s) useful in the treatment compositions may comprise, consist essentially of, or consist of histidine and/or salts thereof. In still other embodiments, the amino acid(s) useful in the treatment compositions may comprise, consist essentially of, or consist of lysine and/or salts thereof. In still further embodiments, the amino acid(s) useful in the compositions may comprise, consist essentially of, or consist of basic amino acids and/or salts thereof.

In various embodiments, the total amount of amino acids may range from about 0.1 % to about 15%, such as about 0.1 % to about 12%, about 0.1% to about 10%, about 0.1 % to about 9%, about 0.1 % to about 8%, about 0.1 % to about 7%, about 0.1 % to about 6%, about 0.1 % to about 5.5%, about 0.1 % to about 5%, about 0.1 % to about 4.5%, about 0.1% to about 4%, about 0.1 % to about 3.5%, about 0.1 % to about 3%, about 0.1 % to about 2.5%, about 0.1 % to about 2%, about 0.1 % to about 1 .5%, about 0.1% to about 1%, about 0.5% to about 15%, about 0.5% to about 12%, about 0.5% to about 10%, about 0.5% to about 9%, about 0.5% to about 8%, about 0.5% to about 7%, about 0.5% to about 6%, about 0.5% to about 5.5%, about 0.5% to about 5%, about 0.5% to about 4.5%, about 0.5% to about 4%, about 0.5% to about 3.5%, about 0.5% to about 3%, about 0.5% to about 2.5%, about 0.5% to about 2%, about 0.5% to about 1.5%, about 0.5% to about 1%, about 1% to about 15%, about 1 % to about 12%, about 1 % to about 10%, about 1% to about 9%, about 1 % to about 8%, about 1 % to about 7%, about 1 % to about 6%, about 1 % to about 5.5%, about 1 % to about 5%, about 1 % to about 4.5%, about 1 % to about 4%, about 1 % to about 3.5%, about 1 % to about 3%, about 1 % to about 2.5%, about 1 % to about 2%, about 1 % to about 1 .5%, about 1 .5% to about 15%, about 1 .5% to about 12%, about 1 .5% to about 10%, about 1 .5% to about 9%, about 1 .5% to about 8%, about 1 .5% to about 7%, about 1 .5% to about 6%, about 1 .5% to about 5.5%, about 1 .5% to about 5%, about 1 .5% to about 4.5%, about 1 .5% to about 4%, about 1 .5% to about 3.5%, about 1 .5% to about 3%, about 1 .5% to about 2.5%, about 1 .5% to about 2%, about 2% to about 15%, about 2% to about 12%, about 2% to about 10%, about 2% to about 9%, about 2% to about 8%, about 2% to about 7%, about 2% to about 6%, about 2% to about 5.5%, about 2% to about 5%, about 2% to about 4.5%, about 2% to about 4%, about 2% to about 3.5%, about 2% to about 3%, about 2% to about 2.5%, about 2.5% to about 15%, about 2.5% to about 12%, about 2.5% to about 10%, about 2.5% to about 9%, about 2.5% to about 8%, about 2.5% to about 7%, about 2.5% to about 6%, about 2.5% to about 5.5%, about 2.5% to about 5%, about 2.5% to about 4.5%, about 2.5% to about 4%, about 2.5% to about 3.5%, about 2.5% to about 3%, about 3% to about 15%, about 3% to about 12%, about 3% to about 10%, about 3% to about 9%, about 3% to about 8%, about 3% to about 7%, about 3% to about 6%, about 3% to about 5.5%, about 3% to about 5%, about 3% to about 4.5%, about 3% to about 4%, about 3% to about 3.5%, about 3.5% to about 15%, about 3.5% to about 12%, about 3.5% to about 10%, about 3.5% to about 9%, about 3.5% to about 8%, about 3.5% to about 7%, about 3.5% to about 6%, about 3.5% to about 5.5%, about 3.5% to about 5%, about 3.5% to about 4.5%, about 3.5% to about 4%, about 4% to about 15%, about 4% to about 12%, about 4% to about 10%, about 4% to about 9%, about 4% to about 8%, about 4% to about 7%, about 4% to about 6%, about 4% to about 5.5%, about 4% to about 5%, about 4% to about 4.5%, about 4.5% to about 15%, about 4.5% to about 12%, about 4.5% to about 10%, about 4.5% to about 9%, about 4.5% to about 8%, about 4.5% to about 7%, about 4.5% to about 6%, about 4.5% to about 5.5%, or about 4.5% to about 5% by weight, relative to the total weight of the composition. In preferred embodiments, the total amount of amino acids ranges from about 2.5% to about 7.5%, about 3% to about 7%, about 3.5% to about 6.5%, about 3.75% to about 6.25%, about 4% to about 6%, about 4.25% to about 5.75%, about 4.5% to about 5.5%, about 4.75% to about 5.25%, or about 4.8% to about 5.2% by weight, relative to the total weight of the composition. For example, the total amount of amino acids may be about 4.5%, about 4.6%, about 4.7%, about 4.8%, about 4.9%, about 5.0%, about 5.1 %, about 5.2%, about 5.3%, about 5.4%, or about 5.5% by weight, relative to the total weight of the composition, including all ranges and subranges using any of the foregoing as upper and lower limits. In some preferred embodiments, the treatment compositions comprise a total amount of basic amino acids in any of the foregoing ranges and amounts.

In one preferred embodiment, the treatment compositions comprise arginine and/or a salt thereof. In another preferred embodiment, where more than one amino acid is present, arginine is present in the treatment composition in an amount greater than the combined amounts of the other amino acid(s) present, for example arginine comprises greater than about 50%, such as greater than about 60%, greater than about 70%, greater than about 80%, greater than about 90%, greater than about 95%, greater than about 98%, or greater than about 99% of all amino acids present in the composition. In a further preferred embodiment, arginine is the only the basic amino acid in the treatment composition.

In various preferred embodiments, the treatment composition comprises arginine in an amount ranging from about 1 % to about 10%, such as from about 2.5% to about 7.5%, preferably from about 3% to about 7%, more preferably from about 3.5% to about 6.5%, more preferably from about 3.75% to about 6.25%, more preferably from about 4% to about 6%, more preferably from about 4.25% to about 5.75%, more preferably still from about 4.5% to about 5.5%, yet more preferably from about 4.75% to about 5.25%, and most preferably from about 4.8% to about 5.2%, or may be present in an amount of about 4.5%, about 4.6%, about 4.7%, about 4.8%, about 4.9%, about 5.0%, about 5.1 %, about 5.2%, about 5.3%, about 5.4%, or about 5.5% by weight, relative to the total weight of the composition, including all ranges and subranges using any of the foregoing as upper and lower limits.

In another preferred embodiment, compositions according to the disclosure comprise serine and/or a salt thereof. If present, the amount of serine may range from about 0.01% to about 2%, such as from about 0.01 % to about 1 .5%, about 0.01 % to about 1 %, about 0.01 % to about 0.5%, about 0.01% to about 0.4%, about 0.01 % to about 0.3%, about 0.01% to about 0.2%, about 0.01 % to about 0.1 %, about 0.05% to about 2%, about 0.05% to about 1.5%, about 0.05% to about 1 %, about 0.05% to about 0.5%, about 0.05% to about 0.4%, about 0.05% to about 0.3%, about 0.05% to about 0.2%, about 0.05% to about 0.1 %, about 0.1 % to about 2%, about 0.1 % to about 1 .5%, about 0.1 % to about 1 %, or about 0.1 % to about 0.5% by weight, relative to the total weight of the composition. For example, in some preferred embodiments, the treatment compositions may comprise serine in an amount ranging from about 0.05% to about 1.5%, preferably from about 0.1 % to about 1 %, more preferably from about 0.25% to about 0.75%, and most preferably from about 0.4% to about 0.6%, such as about 0.1 %, about 0.25%, about 0.5%, about 0.75%, or about 1 % by weight, relative to the total weight of the composition, including all ranges and subranges using any of the foregoing as upper and lower limits.

In some embodiments, it may be advantageous to choose at least one basic amino acid and at least one additional amino acid chosen from acidic and/or neutral amino acids. For example, in preferred embodiments it may be advantageous to include at least one basic amino acid and serine in compositions according to the disclosure, and to choose total amounts of basic amino acids and serine such that the treatment composition has a weight ratio of the total amount of basic amino acids to the total amount of serine that is greater than about 2, such as greater than about 3, greater than about 4, greater than about 5, or greater than about 6. For example, the treatment composition may have a weight ratio of the total amount of basic amino acids to the total amount of serine ranging from about 2 to about 15, such as from about 4 to about 14, from about 6 to about 13, from about 8 to about 12, or from about 9 to about 1 1 . In further examples, the weight ratio of the total amount of basic amino acids to serine may be about 8, about 9, about 10, about 11 , or about 12. In some preferred embodiments, the treatment composition comprises serine and has a weight ratio of the total amount of basic amino acids to serine ranging from about 2 to about 15, preferably from about 8 to about 12, more preferably from about 9 to about 1 1 , or is about 8, about 9, about 10, about 1 1 , or about 12, including all ranges and subranges using any of the foregoing as upper and lower limits.

In still further preferred embodiments, the treatment compositions comprise serine and arginine, and have a weight ratio of arginine to serine ranging from about 2 to about 15, preferably from about 8 to about 12, more preferably from about 9 to about 1 1 , or is about 8, about 9, about 10, about 1 1 , or about 12, including all ranges and subranges using any of the foregoing as upper and lower limits.

Osmolytes Osmolytes are molecules, typically of lower molecular weight, used by cells to maintain cell volume, regulate osmotic pressure, and maintain cellular homeostasis, for example in response to environmental stressors. Organic osmolytes include amino carboxylic acids, amino sulfonic acids, salts thereof, and derivatives thereof, carbohydrates such sugars and sugar alcohols (polyols), polyamines, betaines, methylsulfonium compounds (e.g. dimethylsulfonopropionate), and urea. For purposes of this disclosure, “osmolytes” includes derivatives of amino carboxylic acids, derivatives of amino sulfonic acids, and salts of the derivatives (referred to herein collectively as “amino acid derivatives”), but does not include amino carboxylic acids, amino sulfonic acids, or salts thereof which are described above, and does not include polyols.

Treatment compositions according to the disclosure comprise one or more osmolytes, preferably one or more organic osmolytes. In some embodiments, the treatment compositions comprise more than one osmolyte. Without intending to be bound by theory, it is believed that the use of osmolytes according to the disclosure permits treated hair to maintain moisture equilibrium, thus reducing potential damage to the hair, or restores moisture equilibrium to already-damaged hair, thereby allowing the treated hair to recover strength and/or reduced elasticity associated with healthy hair.

In preferred embodiments, useful osmolytes are chosen from carbohydrate sugars, polyamines, amino acid derivatives such as betaines, and more preferably are chosen from compounds of formula (II) or salts thereof:

(R1 )(R2)(R3)m-A⁺-CR4R5-(X)_n-Y-

(H) wherein:

R1 , R2, and R3 are independently chosen from C1 -C4 alkyl groups, preferably C1 -C2 alkyl groups, more preferably methyl;

A is N or S; m and n are independently 0 or 1 ;

X is a divalent alkyl group (= an alkylene group), linear or branched, saturated or unsaturated, having 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, optionally substituted by one or more groups chosen from hydroxyl (- OH) or amino (-NH2); and

Y’ is -COO- or -OSO3-; with the provisos that: o when A is S, then m = 0 and R4 and R5 are independently chosen from a hydrogen atom or a saturated, unsaturated, linear, branched, and/or cyclic (including aromatic and polycyclic chains), (C1 -C10) hydrocarbon chain, preferably (C1 -C6), more preferably (C1 -C4); optionally interrupted by one or more heteroatoms or groups chosen from -S-, -N=, -NH-, or -C(NH)- and/or optionally substituted by one or more groups chosen from hydroxyl (-OH), amino (-NH2), -SH, -COOH, or -CONH2; o when A is N and m = 0, R4 represents a hydrogen atom or a saturated, linear or branched (C1 -C8)alkyl, preferably (C1 -C4)alkyl, group; and R5 forms, with the nitrogen atom, a saturated heterocycle comprising from 5 to 8 ring members, preferably 5 to 6 ring members, it being possible for this ring to be substituted by one or more groups chosen from hydroxyl or (C1 -C4)alkyl ; and o when A is N and m = 1 , then R4 and R5 are independently chosen from a hydrogen atom or a saturated, unsaturated, linear, branched and/or cyclic (including aromatic and polycyclic chains) (C1 -C10) hydrocarbon chain, preferably (C1 -C6), more preferably (C1 -C4); optionally interrupted by one or more heteroatoms or groups chosen from -S-, -N=, -NH-, or -C(NH)- and/or optionally substituted by one or more groups chosen from hydroxyl (-OH), amino (-NH2), -SH, -COOH, or -CONH2.

Useful and non-limiting polyamine compounds may comprise primary and/or secondary and/or tertiary and/or quaternary amine functional groups. By way of example, polyamines that can be chosen include diamines, triamines, tetramines, pentamines, and polymeric polyamines or polyimines, such as, for example, hexamethylenediamine, diethylenetetramine, diethylenetriamine, polyethyleneimine (PEI), polyvinyl amine, polyether amine, polylysine, ethylene diamine, 1 ,3- diaminopropane, cadaverine, spermidine, spermine, putrescine, tetraethylmethylenediamine, triethylenetetramine, or combinations of two or more thereof. In some embodiments, useful polyamines are chosen from putrescine, spermidine, and/or spermine.

Useful and nonlimiting examples of betaines include glycine betaine, valine betaine, alanine betaine, proline betaine, hydroxyproline betaine, etc. Salts of betaines can also be used and are expressly included in the term “betaine” unless expressly stated otherwise. In particularly preferred embodiments, betaines are chosen from those corresponding to formula (II). Exemplary useful compounds of formula (II) include the compounds shown in FIGS. 1 A-1 B. As shown in FIG. 1 A, in some embodiments the compounds of formula (II) are in zwitterionic form, and as shown in FIG. 1 B, in some embodiments the compounds of formula (II) have a corresponding counterion, X’. The counterion is not limited, and can be any suitable counterion, for example a chloride ion, bromide ion, iodide ion, sulfate anion, sulfonate anion, methyl sulfate anion, phosphate anion, nitrate anion, etc. Thus, as used herein a “compound of formula (II)” expressly includes both the ionic form of the compound as well as salt forms, whether or not so stated.

As shown in FIGS. 1 A-1 B, exemplary useful compounds of formula (II) include betaine and betaine derivatives (referred to herein as “betaines”), for example valine betaine, glutamic acid betaine, glutamine betaine, trimethyl lysine, glycine betaine (trimethyl glycine), histidine betaine, N-methyl histidine betaine, alanine betaine, beta-alanine betaine, choline sulfate, pipecolic acid betaine, proline betaine, hydroxyproline betaine, tyrosine betaine, phenylalanine betaine, tryptophan betaine, leucine betaine, isoleucine betaine, and/or dimethylsulfoniopropionate. In a preferred embodiment, the osmolyte is glycine betaine (trimethyl glycine), alone or in combination with one or more additional osmolytes, for example one or more additional compounds of formula (II).

In some preferred embodiments, treatment compositions that can be used according to the disclosure comprise at least one compound of formula (II). In additional preferred embodiments, compositions according to the disclosure comprise one or more compounds of formula (II) that is a zwitterionic amino acid derivative bearing a quaternary ammonium group and comprising in total from 1 to 12 carbon atoms, such as from 2 to 10 carbon atoms, or from 3 to 8 carbon atoms.

In some preferred embodiments, treatment compositions comprise at least one compound of formula (II) wherein R1 = R2 = methyl; A is N; and/or Y is COO- . In some other preferred embodiments, treatment compositions comprise at least one compound of formula (II) wherein R3 is methyl. In other preferred embodiments, treatment compositions comprise at least one compound of formula (II) wherein X is a divalent alkyl group, linear or branched, preferably saturated, having from 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, optionally substituted by one group chosen from hydroxyl or amino. In still other preferred embodiments, treatment compositions comprise at least one compound of formula (II) wherein X is a divalent alkyl group, linear or branched, preferably saturated, having from 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, more preferably 1 to 2 carbon atoms (not substituted), such as methylene or ethylene. In other preferred embodiments, treatment compositions comprise at least one compound of formula (II) wherein R4 and R5, which may be the same or different, are chosen from a hydrogen atom, a saturated, linear or branched (C1 -C10) alkyl group, preferably (C1 -C6)alkyl, more preferably (C1 -C4) alkyl; a phenyl group; a benzyl group; an alkyl group substituted by a cyclic group (saturated or not, mono or bi-cyclic); a cyclic group (saturated or not, mono or bi-cyclic) substituted by an alkyl group; all these groups being optionally interrupted by one or more heteroatoms or groups chosen from -S-, -N=, -NH-, or -C(NH)- and/or optionally substituted by one or more groups chosen from hydroxyl (-OH), amino (-NH2), -SH, -COOH, -CONH2; more preferably where R4 is hydrogen and/or where R5 is a hydrogen atom or a saturated, linear or branched (C1 -C6)alkyl, more preferably (C1 -C4) alkyl; optionally substituted by one group chosen from hydroxyl (-OH), amino (-NH2), -COOH, or -CONH2. In some preferred embodiments, when A is N and m = 0, R5 forms, together with the nitrogen atom, a saturated heterocycle comprising from 5 to 8 ring members, preferably 5 to 6 ring members, optionally substituted by one hydroxy group. In further preferred embodiments, R1 = R2 = methyl, A is N, Y is COO-, and X (if present) is a divalent alkyl group that may be linear or branched, saturated or unsaturated, having from 1 to 6 carbon atoms, preferably from 1 to 4 carbon atoms, more preferably from 1 to 2 carbon atoms.

In one preferred embodiment, the treatment composition comprises at least one compound of formula (II) wherein R1 = R2 = R3 = methyl; A is N; Y is COO- ; X is a divalent alkyl group, linear or branched, preferably saturated, having from 1 to 4 carbon atoms, optionally substituted by one group chosen from hydroxyl or amino, more preferably 1 to 2 carbon atoms (not substituted), such as methylene or ethylene; R4 is hydrogen; and R5 forms, together with the nitrogen atom, a saturated heterocycle comprising from 5 to 8 ring members, preferably 5 to 6 ring members, optionally substituted by one hydroxy group.

In preferred embodiments, the osmolyte in the treatment composition comprises, consists essentially of, or consists of one or more of the compounds shown in FIGS. 1 A-1 B. In more preferred embodiments, compositions according to the disclosure comprise trimethyl glycine (referred to interchangeably as glycine betaine), optionally in combination with at least one additional osmolyte, and in particularly preferred embodiments the osmolyte in the treatment composition comprises, consists essentially of, or consists of glycine betaine optionally with at least one additional compound of formula (II).

Useful and non-limiting examples of carbohydrate sugars that can be used include C3-C6 monosaccharides, for example pentoses and/or derivatives thereof, or hexoses and/or derivatives thereof. For example, the sugars may optionally be chosen from chosen from xylose, arabinose, ribose, 2-deoxy-ribose, ribulose, deoxy-ribulose, arabinose, xylulose, allose, altrose, glucose (including dextrose), glucosamine, mannose, gulose, idose, galactose, talose, sorbose, psicose, fructose, tagatose, or combinations of two or more thereof. In at least some embodiments, the sugars are chosen from disaccharides, for example sucrose (also saccharose), maltose, lactose, cellobiose, trehalose, dextran, or from polysaccharides, for example maltotriose, starch, dextrins, cellulose, glycogen, or combinations of two or more thereof. In some embodiments, the sugars are preferably chosen from trehalose, glucose, sucrose, fructose, fructans, or combinations of two or more thereof.

In various embodiments, the total amount of osmolytes present in the treatment composition may range from about 0.01% to about 15%, such as, for example, from about 0.1 % to about 10%, from about 0.1 % to about 9%, from about 0.1 % to about 8%, from about 0.1 % to about 7%, from about 0.1 % to about 6%, from about 0.1 % to about 5%, from about 0.1 % to about 4%, from about 0.1 % to about 3%, from about 0.1 % to about 2%, from about 0.1 % to about 1 %, from about 0.5% to about 10%, from about 0.5% to about 9%, from about 0.5% to about 8%, from about 0.5% to about 7%, from about 0.5% to about 6%, from about 0.5% to about 5%, from about 0.5% to about 4%, from about 0.5% to about 3%, from about 0.5% to about 2%, from about 0.5% to about 1%, from about 1 % to about 10%, from about 1 % to about 9%, from about 1 % to about 8%, from about 1 % to about 7%, from about 1 % to about 6%, from about 1 % to about 5%, from about 1 % to about 4%, from about 1 % to about 3%, from about 1 % to about 2%, from about 1 .5% to about 10%, from about 1 .5% to about 9%, from about 1 .5% to about 8%, from about 1 .5% to about 7%, from about 1 .5% to about 6%, from about 1 .5% to about 5%, from about 1 .5% to about 4%, from about 1 .5% to about 3%, from about 1 .5% to about 2%, from about 2% to about 10%, from about 2% to about 9%, from about 2% to about 8%, from about 2% to about 7%, from about 2% to about 6%, from about 2% to about 5%, from about 2% to about 4%, from about 2% to about 3%, from about 2.25% to about 10%, from about 2.25% to about 9%, from about 2.25% to about 8%, from about 2.25% to about 7%, from about 2.25% to about 6%, from about 2.25% to about 5%, from about 2.25% to about 4%, from about 2.25% to about 3%, from about 2.5% to about 10%, from about 2.5% to about 9%, from about 2.5% to about 8%, from about 2.5% to about 7%, from about 2.5% to about 6%, from about 2.5% to about 5%, from about 2.5% to about 4%, from about 2.5% to about 3% by weight, relative to the total weight of the composition. For example, the total amount of osmolytes present in the treatment composition may be about 2.0%, about 2.1 %, about 2.2%, about 2.3%, about 2.4%, about 2.5%, about 2.6%, about 2.7%, about 2.8%, about 2.9%, or about 3.0% by weight, relative to the total weight of the composition, including all ranges and subranges using any of the foregoing as upper and lower limits.

In preferred embodiments, the treatment composition comprises at least one betaine, and the total amount of betaines ranges from about 0.5% to about 5%, for example from about 1 % to about 5%, preferably from about 1.25% to about 4%, more preferably from about 1 .5% to about 3.5%, more preferably from about 2% to about 3% or from about 2% to about 2.5%, more preferably still from about 2.25% to about 2.75%, and most preferably from about 2.3% to about 2.6%, or may be about 2.0%, about 2.1 %, about 2.2%, about 2.3%, about 2.4%, about 2.5%, about 2.6%, about 2.7%, about 2.8%, about 2.9%, or about 3.0% by weight, relative to the total weight of the composition, including all ranges and subranges using any of the foregoing as upper and lower limits.

In a particularly preferred embodiment, the treatment composition comprises glycine betaine in an amount ranging from about 0.5% to about 5%, for example about 1 % to about 5%, preferably from about 1.25% to about 4%, more preferably from about 1 .5% to about 3.5%, more preferably from about 2% to about 3% or from about 2% to about 2.5%, more preferably still from about 2.25% to about 2.75%, and most preferably from about 2.3% to about 2.6%, or the glycine betaine may be present in an amount of about 2.0%, about 2.1 %, about 2.2%, about 2.3%, about 2.4%, about 2.5%, about 2.6%, about 2.7%, about 2.8%, about 2.9%, or about 3.0% by weight, relative to the total weight of the composition, including all ranges and subranges using any of the foregoing as upper and lower limits.

It may be advantageous, in some embodiments, to choose amounts of amino acids and osmolytes to provide a weight ratio of the total amount of amino acid(s) and salts thereof in the treatment composition to the total amount of osmolytes in the treatment composition that is greater than about 0.1 , for example greater than about 0.2, greater than about 0.5, greater than about 1 , greater than about 1 .25, greater than about 1.5, greater than about 1.75, or greater than about 2. In various embodiments, the weight ratio of the total amount of amino acid(s) and salts thereof to the total amount of osmolytes may range from about 0.1 to about 10, such as from about 0.2 to about 8, from about 0.5 to about 6, from about 1 to about 5, from about 1 .2 to about 4, or from about 1 .5 to about 3.5. In other embodiments, the weight ratio of the total amount of amino acid(s) and salts thereof to the total amount of osmolytes may range from greater than 1 to about 4, such as from about 1 .25 to about 3.5, from about 1 .5 to about 3, from about 1 .75 to about 2.5, from about 1 .75 to about 2.25, or from about 1 .8 to about 2.2. For example, the weight ratio of the total amount of amino acid(s) in the treatment composition to the total amount of osmolytes in the treatment composition may be about 1.1 , about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1 .7, about 1 .8, about 1 .9, about 2, about 2.1 , about 2.2, about 2.3, about 2.4, or about 2.5, including all ranges and subranges using any of the foregoing as upper and lower limits.

In some embodiments, the treatment compositions comprise a total amount of amino acids chosen from compounds of formula (I), and a total amount of osmolytes chosen from compounds of formula (II) such that a weight ratio of compounds of formula (l):compounds of formula (II) is greater than about 0.5, greater than about 0.75, or greater than about 1 , for example greater than about 1 .25, greater than about 1.5, greater than about 1.75, or greater than about 2. In some embodiments, the weight ratio of compounds of formula (l):compounds of formula (II) in the composition may range from about 0.5 to about 6, for example from about 1 to about 4, from about 1.25 to about 3.5, from about 1.5 to about 3, from about 1.75 to about 2.5, from about 1 .75 to about 2.25, or from about 1 .8 to about 2.2. For example, the weight ratio of compounds of formula (l):compounds of formula (II) in the composition may be about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1 , about 1.1 , about 1 .2, about 1 .3, about 1 .4, about 1 .5, about 1 .6, about 1 .7, about 1 .8, about 1 .9, about 2, about 2.1 , about 2.2, about 2.3, about 2.4, or about 2.5, including all ranges and subranges using any of the foregoing as upper and lower limits.

In a particularly preferred embodiment, the treatment composition comprises arginine and glycine betaine and has a weight ratio of arginine to glycine betaine of greater than 1 , for example greater than about 1 .25, greater than about 1 .5, greater than about 1 .75, or greater than about 2, for example ranging from greater than 1 to about 4, preferably from about 1 .5 to about 3, more preferably from about 1 .75 to about 2.5, and most preferably from about 1 .75 to about 2.25. In another particularly preferred embodiment, the treatment composition comprises arginine, serine, and glycine betaine and has a weight ratio of the total amount of [arginine + serine] to glycine betaine of greater than 1 , for example greater than about 1 .25, greater than about 1 .5, greater than about 1 .75, or greater than about 2, for example ranging from greater than 1 to about 4, preferably from about 1 .5 to about 3, more preferably from about 1 .75 to about 2.5, and most preferably from about 1 .75 to about 2.25.

Carboxylic Acids

Treatment compositions that can be used in methods according to the disclosure include at least one carboxylic acid. Optionally, the treatment compositions may comprise at least two carboxylic acids, at least three carboxylic acids, etc. According to various embodiments of the disclosure, useful carboxylic acids include organic compounds that include, for example, one (mono-), two (di-), three (tri-), or more acid functional groups and at least one carbon atom.

Carboxylic acids that can be used may optionally have a molecular weight of less than about 500 g/mol, less than about 400 g/mol, less than about 300 g/mol, or less than about 200 g/mol. In preferred embodiments, the carboxylic acids have a molecular weight of less than about 300 g/mol, or less than about 200 g/mol.

Salts of carboxylic acids can also be used and are expressly included in the term “carboxylic acid” unless expressly stated otherwise. The salts include salts with organic or mineral bases, for example the salts of alkali metals, such as the lithium, sodium, or potassium salts; the salts of alkaline earth metals, such as the magnesium or calcium salts, and the zinc salts. The alkali metal or alkaline earth metal salts are preferred in some embodiments, and in particular the sodium salts.

In preferred embodiments, carboxylic acids comprise from 2 to 20 carbon atoms, such as from 2 to 18 carbon atoms, from 3 to 16 carbon atoms, or from 3 to 14 carbon atoms. In some preferred embodiments, the treatment compositions comprise one or more hydroxylated (poly)carboxylic acids comprising from 2 to 10 carbon atoms, such as from 2 to 8 carbon atoms, or from 3 to 6 carbon atoms, and may be saturated or unsaturated, and linear or branched, and/or a salt thereof. These (poly)acids are different from the compounds of amino acids type described above. Useful (poly)acids comprise at least one -COOH group (in acid or salified form); they can thus comprise a single -COOH group (monoacid) or can comprise more than one, for example two - COOH groups (in acid or salified form), or two or three -COOH groups (in acid or salified form) (polyacids). Useful (poly)acids also comprise at least one -OH group, such as from one to three or from two to three -OH groups, for example one, two, or three -OH groups. Preferably, the (poly)acids comprise in total from 2 to 8 or from 3 to 6 carbon atoms, and from two to three -OH groups, and their hydrocarbon chain is saturated or unsaturated, linear or branched, and preferably saturated and linear. In some preferred embodiments, the hydroxylated (poly)carboxylic acids and/or their salts comprise in total from 3 to 6 carbon atoms, from one to three -OH groups, and from two to three -COOH groups (in acid or salified form). Unless stated otherwise, as used herein the term “(poly)acid” includes both monoacids and polyacids.

Non-limiting examples of monocarboxylic acids that can be chosen include formic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, enanthic acid, caprylic acid, lactic acid, salts thereof, or combinations of two or more thereof. In some embodiments, the carboxylic acid may comprise, consist essentially of, or consist of lactic acid and/or a salt thereof.

Non-limiting examples of dicarboxylic acids that can be chosen include oxalic acid, malonic acid, malic acid, glutaric acid, citraconic acid, succinic acid, adipic acid, tartaric acid, fumaric acid, maleic acid, salts thereof, or combinations of two or more thereof. In some embodiments, the treatment compositions may include oxalic acid, malonic acid, malic acid, maleic acid, salts thereof, or combinations of two or more thereof.

Non-limiting examples of tricarboxylic acids include citric acid, isocitric acid, aconitic acid, propane-1 ,2,3-tricarboxylic acid, salts thereof, or combinations of two or more thereof. In some embodiments, the carboxylic acid may comprise, consist essentially of, or consist of citric acid and/or a salt thereof.

In some embodiments, the carboxylic acid(s) may be chosen from oxalic acid, malonic acid, glutaric acid, succinic acid, adipic acid, glycolic acid, citric acid, tartaric acid, malic acid, maleic acid, lactic acid, salts thereof, or combinations of two or more thereof. In particularly preferred embodiments, the carboxylic acids are chosen from a-hydroxy acids and their salts, and in particular from lactic acid, glycolic acid, tartaric acid, or citric acid, and their salts, in particular alkali metal or alkaline earth metal salts. It may in some embodiments be particularly advantageous to choose citric acid, lactic acid, and/or tartaric acid and/or their salts, in particular alkali metal or alkaline earth metal salts, such as sodium citrate and/or sodium tartrate; preferably citric acid and/or its salts, in particular alkali metal or alkaline earth metal salts, such as sodium citrate.

The total amount of carboxylic acid(s) may range from about 0.5% to about 20% by weight, relative to the total weight of the composition. For example, in some embodiments, the total amount of carboxylic acids ranges from about 1 % to about 15%, such as about about 1 % to about 12%, about 1 % to about 10%, about 1 % to about 9%, about 1 % to about 8%, about 1 % to about 7%, about 1 % to about 6%, about 1 % to about 5.5%, about 1 % to about 5%, about 1 % to about 4.5%, about 1 % to about 4%, about 1 % to about 3.5%, about 1 % to about 3%, about 1 % to about 2.5%, about 1 % to about 2%, about 1 % to about 1 .5%, about 1 .5% to about 15%, about 1 .5% to about 12%, about 1 .5% to about 10%, about 1 .5% to about 9%, about 1 .5% to about 8%, about 1 .5% to about 7%, about 1 .5% to about 6%, about 1 .5% to about 5.5%, about 1 .5% to about 5%, about 1 .5% to about 4.5%, about 1 .5% to about 4%, about 1 .5% to about 3.5%, about 1 .5% to about 3%, about 1 .5% to about 2.5%, about 1 .5% to about 2%, about 2% to about 15%, about 2% to about 12%, about 2% to about 10%, about 2% to about 9%, about 2% to about 8%, about 2% to about 7%, about 2% to about 6%, about 2% to about 5.5%, about 2% to about 5%, about 2% to about 4.5%, about 2% to about 4%, about 2% to about 3.5%, about 2% to about 3%, about 2% to about 2.5%, about 2.5% to about 15%, about 2.5% to about 12%, about 2.5% to about 10%, about 2.5% to about 9%, about 2.5% to about 8%, about 2.5% to about 7%, about 2.5% to about 6%, about 2.5% to about 5.5%, about 2.5% to about 5%, about 2.5% to about 4.5%, about 2.5% to about 4%, about 2.5% to about 3.5%, about 2.5% to about 3%, about 3% to about 15%, about 3% to about 12%, about 3% to about 10%, about 3% to about 9%, about 3% to about 8%, about 3% to about 7%, about 3% to about 6%, about 3% to about 5.5%, about 3% to about 5%, about 3% to about 4.5%, about 3% to about 4%, about 3% to about 3.5%, about 3.5% to about 15%, about 3.5% to about 12%, about 3.5% to about 10%, about 3.5% to about 9%, about 3.5% to about 8%, about 3.5% to about 7%, about 3.5% to about 6%, about 3.5% to about 5.5%, about 3.5% to about 5%, about 3.5% to about 4.5%, about 3.5% to about 4%, about 4% to about 15%, about 4% to about 12%, about 4% to about 10%, about 4% to about 9%, about 4% to about 8%, about 4% to about 7%, about 4% to about 6%, about 4% to about 5.5%, about 4% to about 5%, about 4% to about 4.5%, about 4.5% to about 15%, about 4.5% to about 12%, about 4.5% to about 10%, about 4.5% to about 9%, about 4.5% to about 8%, about 4.5% to about 7%, about 4.5% to about 6%, about 4.5% to about 5.5%, about 4.5% to about 5%, about 5% to about 15%, about 5% to about 12%, about 5% to about 10%, about 5% to about 9%, about 5% to about 8%, about 5% to about 7%, about 5% to about 6.5%, about 5% to about 6%, about 5% to about 5.5%, about 5.5% to about 15%, about 5.5% to about 12%, about 5.5% to about 10%, about 5.5% to about 9%, about 5.5% to about 8%, about 5.5% to about 7%, about 5.5% to about 6.5%, about 5.5% to about 6%, about 6% to about 15%, about 6% to about 12%, about 6% to about 10%, about 6% to about 9%, about 6% to about 8%, about 6% to about 7%, or about 6% to about 6.5% by weight, relative to the total weight of the composition.

In preferred embodiments, the total amount of carboxylic acid(s) ranges from about 0.5% to about 20%, such as from about 2% to about 15%, from about 4% to about 10%, about 4.5% to about 8%, about 5% to about 7%, about 5.5% to about 6.5%, about 5.7% to about 6.3%, or about 5.8% to about 6.2% by weight, relative to the total weight of the composition. For example, in some preferred embodiments, the treatment composition comprises at least one carboxylic acid chosen from citric acid, lactic acid, tartaric acid, salts thereof, or combinations thereof, and has a total amount of carboxylic acids and salts ranging from about 0.5% to about 20%, such as from about 2% to about 15%, from about 4% to about 10%, preferably from about 4.5% to about 8%, more preferably from about 5% to about 7%, more preferably from about 5.5% to about 6.5%, more preferably still from about 5.7% to about 6.3%, and most preferably from about 5.8% to about 6.2% by weight, relative to the total weight of the composition.

It may be advantageous in some embodiments to choose amounts of amino acids and carboxylic acids such that the treatment composition has a weight ratio of the total amount of amino acids to the total amount of carboxylic acids of greater than about 0.75. For example, in various embodiments, the treatment composition has a weight ratio of the total amount of amino acids to the total amount of carboxylic acids of greater than about 0.8, such as greater than about 0.9, greater than about 1 , greater than about 1.1 , greater than about 1 .2, greater than about 1 .3, greater than about 1 .4, or greater than about 1 .5. In some embodiments, the treatment composition has a weight ratio of the total amount of amino acids to the total amount of carboxylic acids ranging from about 0.75 to about 2, such as from about 0.8 to about 1 .5, from about 0.8 to about 1 .35, or from about 0.8 to about 1 .2. In some preferred embodiments, the treatment composition comprises arginine and at least one carboxylic acid chosen from citric acid, lactic acid, tartaric acid, salts thereof, or combinations thereof, and has a weight ratio of the total amount of amino acids and salts thereof to the total amount of carboxylic acids and salts thereof ranging from about 0.75 to about 2, preferably from about 0.8 to about 1.5, more preferably from about 0.8 to about 1.35, and most preferably from about 0.8 to about 1 .2.

Solvents

Treatment compositions that can be used in methods according to the disclosure comprise at least one solvent. In various embodiments, solvents may be chosen from water, non-aqueous solvents, or a combination thereof.

In preferred embodiments, the solvent includes water. In certain embodiments, the treatment composition comprises from about 50% to about 98% of water, by weight, relative to the total weight of the composition. In certain embodiments, the treatment composition comprises water in an amount ranging from about 50% to about 95% water by weight, such as from about 50% to about 90%, about 55% to about 90%, about 60% to about 90%, or about 60% to about 80% by weight, relative to the total weight of the composition. n further embodiments, the solvent may include at least one non-aqueous solvent. Exemplary and non-limiting non-aqueous solvents that can be used include, for example, glycerin, Ci-4 alcohols, organic solvents, fatty alcohols, fatty ethers, fatty esters, polyols, glycols, vegetable oils, mineral oils, liposomes, laminar lipid materials, or combinations thereof. The non-aqueous solvent may be chosen from organic solvents, for example, monoalcohols and polyols such as ethyl alcohol, isopropyl alcohol, propyl alcohol, benzyl alcohol, and phenylethyl alcohol, or glycols or glycol ethers such as, for example, monomethyl, monoethyl and monobutyl ethers of ethylene glycol, propylene glycol or ethers thereof such as, for example, monomethyl ether of propylene glycol, butylene glycol, hexylene glycol, dipropylene glycol as well as alkyl ethers of diethylene glycol, for example monoethyl ether or monobutyl ether of diethylene glycol.

Preferably, the compositions comprise at least one polyol. The polyols can be chosen from diols and triols. In other embodiments, the polyols can be chosen from C2-C16 polyols, such as C2-C12 polyols, C2-C8 polyols, or C3-C8 polyols. In various embodiments, the polyols that can be used are linear or branched, saturated or unsaturated, and substituted or unsubstituted polyols. Thus, in various embodiments, one or more polyols can be chosen from C2-C16, C2-C12, C2-C8, or C3-C8 diols, or C2-C16, C2-C12, C2-C8, or C3-C8 triols, any of which may be linear or branched, saturated or unsaturated, and substituted or unsubstituted.

By way of non-limiting example, polyols such as isopropyl alcohol, propyl alcohol, benzyl alcohol, and phenylethyl alcohol, or glycols or glycol ethers such as, for example, monomethyl, monoethyl, and monobutyl ethers of ethylene glycol, propylene glycol or ethers thereof such as, for example, monomethyl ether of propylene glycol, butylene glycol, hexylene glycol, dipropylene glycol as well as alkyl ethers of diethylene glycol, for example monoethyl ether or monobutyl ether of diethylene glycol may be chosen. In some embodiments, the polyols are chosen from propanediol, butanediol, pentanediol, hexanediol, heptanediol, octanediol, 1 ,2,6- hexanetriol, 1 ,2,4-butanetriol, trimethylolpropane, 2-butene-1 ,4-diol, 2-ethyl-1 ,3- hexanediol, 2-methyl-2,4-pentanediol, caprylyl glycol, 1 ,2-hexanediol, 1 ,2-pentanediol, 2-ethyl-2-methyl-1 ,3-propanediol, 3,3-dimethyl-1 ,2-butanediol, 2,2-diethyl- 1 ,3- propanediol, 2-methyl-2-propyl-1 ,3-propanediol, 2,4-dimethyl-2,4-pentanediol, 2,5- dimethyl-2,5-hexanediol, 5-hexene-1 ,2-diol, 2-ethyl-1 ,3-hexanediol, 4-methyl-1 ,2- pentanediol, or combinations of two or more thereof. In some preferred embodiments, the polyols are chosen from glycols such as ethylene glycol, propylene glycol, butylene glycol, hexylene glycol, pentylene glycol, 1 ,3-propanediol, diethylene glycol, triethylene glycol, tetraethylene glycol, pentaethylene glycol, dipropylene glycol, caprylyl glycol, glycerin, diglycerin, and combinations of two or more thereof. In a particularly preferred embodiment, the solvent comprises at least one polyol chosen from propylene glycol, dipropylene glycol, tripropylene glycol, propanediol, propylene carbonate, PPG-3 methyl ether, dimethyl isosorbide, hexylene glycol, ethanol, glycerin, or combinations of two or more thereof. In at least certain preferred embodiments, the solvent comprises water and at least one polyol, wherein the polyol(s) comprises, consists essentially of, or consists of one or more C2-C16 diols and/or C2-C16 triols, for example C2-C8 diols and/or C2-C8 triols. In other preferred embodiments, the solvent comprises water and at least one polyol, wherein the polyol(s) comprises, consists essentially of, or consists of one or more glycols, for example propylene glycol and/or dipropylene glycol, and in particularly preferred embodiments, the solvent comprises water and at least one polyol, wherein the polyol(s) comprises, consists essentially of, or consists of dipropylene glycol. If present, the total amount of the non-aqueous solvents in the treatment composition may range from about 0.1% to about 20%, such as from about 1 % to about 20%, from about 1 .5% to about 15%, or from about 2% to about 12% by weight, relative to the total weight of the composition. In some preferred embodiments, the solvent comprises water and at least one non-aqueous solvent, preferably chosen from polyols. In some embodiments, the treatment composition comprises water and at least one non-aqueous solvent, wherein the total amount of non-aqueous solvents ranges from about 0.5% to about 18%, preferably from about 1% to about 15%, more preferably from about 1 .5% to about 12%, more preferably still from about 2% to about 1 1 %, and most preferably from about 3% to about 10% by weight, relative to the total weight of the composition, and optionally further wherein the non-aqueous solvent comprises at least one solvent chosen from propylene glycol, dipropylene glycol, tripropylene glycol, propanediol, propylene carbonate, PPG-3 methyl ether, dimethyl isosorbide, hexylene glycol, ethanol, or mixtures of two or more thereof, preferably chosen from propylene glycol, dipropylene glycol, or a mixture of two or more thereof.

Surfactants

Treatment compositions that can be used in methods according to the disclosure may optionally comprise at least one surfactant. For example, the treatment compositions may comprise one or more cationic surfactants and/or amphoteric surfactants, and in some embodiments the compositions may comprise mixtures of surfactants having the same or different ionicities.

Although the treatment compositions may optionally include one or more anionic surfactants and/or nonionic surfactants, in at least some embodiments, the compositions are free or substantially free of anionic surfactants and/or nonionic surfactants. For example, in some embodiments the compositions comprise less than about 3%, such as less than about 2.5%, less than about 2%, less than about 1 .75%, less than about 1.5%, less than about 1.25%, less than about 1%, less than about 0.75%, less than about 0.5%, less than about 0.25%, less than about 0.2%, less than about 0.1 %, less than about 0.05%, less than about 0.01 %, or less than about 0.001 % of anionic surfactants and/or nonionic surfactants.

In at least some embodiments, treatment compositions comprise at least one cationic surfactant. The term “cationic surfactant” means a surfactant that is positively charged when it is contained in the composition(s) according to the disclosure. This surfactant may bear one or more positive permanent charges or may contain one or more functions that are cationizable in the composition according to the disclosure. Non-limiting examples of useful cationic surfactants include brassicamidopropyl dimethylamine, behentrimonium chloride, cetrimonium chloride, behenalkonium chloride, benzethonium chloride, cetylpyridinium chloride, behentrimonium chloride, lauralkonium chloride, cetalkonium chloride, cetrimonium bromide, cethylamine hydrofluoride, chlorallylmethenamine chloride (Quaternium-15), distearyldimonium chloride (Quaternium-5), dodecyl dimethyl ethylbenzyl ammonium chloride (Quaternium-14), Quaternium-22, Quaternium-26, Quaternium-18 hectorite, dimethylaminoethylchloride hydrochloride, cysteine hydrochloride, diethanolammonium POE (10) oletyl ether phosphate, diethanolammonium POE (3)oleyl ether phosphate, tallow alkonium chloride, dimethyl dioctadecylammoniumbentonite, stearalkonium chloride, domiphen bromide, denatonium benzoate, myristalkonium chloride, laurtrimonium chloride, ethylenediamine dihydrochloride, guanidine hydrochloride, pyridoxine HCI, iofetamine hydrochloride, meglumine hydrochloride, methylbenzethonium chloride, myrtrimonium bromide, oleyltrimonium chloride, polyquaternium-1 , procainehydrochloride, cocobetaine, stearalkonium bentonite, stearalkoniumhectonite, stearyl trihydroxyethyl propylenediamine dihydrofluoride, tallowtrimonium chloride, hexadecyltrimethyl ammonium bromide, stearamidopropyl dimethylamine, or combinations thereof. In preferred embodiments, the compositions comprise at least one cationic surfactant chosen from brassicamidopropyl dimethylamine, behentrimonium chloride, cetrimonium chloride, stearamidopropyl dimethylamine, or combinations of two or more thereof.

If present, the total amount of cationic surfactants may range up to about 10%, such as up to about 9%, up to about 8%, up to about 7%, up to about 6%, up to about 5%, up to about 4%, up to about 3.5%, up to about 3%, up to about 2.5%, up to about 2%, up to about 1 .5%, up to about 1 %, or up to about 0.5% by weight, relative to the total weight of the composition. For example, the total amount of cationic surfactants may range from about 0.001 % to about 10%, from about 0.01 % to about 8%, from about 0.1 % to about 6%, or from about 0.5% to about 4% by weight, relative to the total weight of the composition. In at least some preferred embodiments, the treatment compositions comprise at least one cationic surfactant, and have a total amount of cationic surfactants ranging from about 0.25% to about 8%, preferably from about 0.5% to about 7%, more preferably from about 0.75% to about 6%, and most preferably from about 1 % to about 5% by weight, relative to the total weight of the composition.

In at least some embodiments, treatment compositions comprise at least one amphoteric surfactant. Non-limiting examples of useful amphoteric surfactants include derivatives of aliphatic secondary and tertiary amines where the aliphatic radical can be straight or branched chain and one of the aliphatic substituents contains from about 8 to about 18 carbon atoms and one contains an anionic group such as carboxy, sulfonate, sulfate, phosphate, or phosphonate. Exemplary amphoteric surfactants include sodium cocaminopropionate, sodium cocaminodipropionate, sodium cocoamphoacetate, sodium cocoamphohydroxypropylsulfonate, sodium cocoamphopropionate, sodium cornamphopropionate, sodium lauraminopropionate, sodium lauroamphoacetate, sodium lauroamphohydroxypropylsulfonate, sodium lauroamphopropionate, sodium cornamphopropionate, sodium lauriminodipropionate, ammonium cocaminopropionate, ammonium cocaminodipropionate, ammonium cocoamphoacetate, ammonium cocoamphohydroxypropylsulfonate, ammonium cocoamphopropionate, ammonium cornamphopropionate, ammonium lauraminopropionate, ammonium lauroamphoacetate, ammonium lauroamphohydroxypropylsulfonate, ammonium lauroamphopropionate, ammonium cornamphopropionate, ammonium lauriminodipropionate, triethanonlamine cocaminopropionate, triethanonlamine cocaminodipropionate, triethanonlamine cocoamphoacetate, triethanonlamine cocoamphohydroxypropylsulfonate, triethanonlamine cocoamphopropionate, triethanonlamine cornamphopropionate, triethanonlamine lauraminopropionate, triethanonlamine lauroamphoacetate, triethanonlamine lauroamphohydroxypropylsulfonate, triethanonlamine lauroamphopropionate, triethanonlamine cornamphopropionate, triethanonlamine lauriminodipropionate, cocoamphodipropionic acid, disodium caproamphodiacetate, disodium caproamphoadipropionate, disodium capryloamphodiacetate, disodium capryloamphodipriopionate, disodium cocoamphocarboxyethylhydroxypropyl- sulfonate, disodium cocoamphodiacetate, disodium cocoamphodipropionate, disodium dicarboxyethylcocopropylenediamine, disodium laureth-5 carboxyamphodiacetate, disodium lauriminodipropionate, disodium lauroamphodiacetate, disodium lauroamphodipropionate, disodium oleoamphodipropionate, disodium PPG-2-isodecethyl-7 carboxyamphodiacetate, lauraminopropionic acid, lauroamphodipropionic acid, lauryl aminopropylglycine, and lauryl diethylenediaminoglycine.

Betaine surfactants may also be used. For example, coco dimethyl carboxymethyl betaine, lauryl dimethyl carboxymethyl betaine, lauryl dimethyl alphacarboxyethyl betaine, cetyl dimethyl carboxymethyl betaine, cetyl dimethyl betaine, lauryl bis-(2-hydroxyethyl) carboxymethyl betaine, stearyl bis-(2- hydroxypropyl) carboxymethyl betaine, oleyl dimethyl gamma-carboxypropyl betaine, lauryl bis-(2-hydroxypropyl) alpha-carboxyethyl betaine, coco dimethyl sulfopropyl betaine, stearyl dimethyl sulfopropyl betaine, lauryl dimethyl sulfoethyl betaine, lauryl bis-(2-hydroxyethyl) sulfopropyl betaine, oleyl betaine, or cocamidopropyl betaine may be chosen.

If present, the total amount of amphoteric surfactants may range up to about 10%, such as up to about 9%, up to about 8%, up to about 7%, up to about 6%, up to about 5%, up to about 4%, up to about 3.5%, up to about 3%, up to about 2.5%, up to about 2%, up to about 1.5%, up to about 1 %, or up to about 0.5% by weight, relative to the total weight of the composition. For example, the total amount of amphoteric surfactants may range from about 0.001 % to about 6%, from about 0.01 % to about 4%, from about 0.1 % to about 3%, or from about 0.5% to about 2% by weight, relative to the total weight of the composition. In at least some embodiments, the treatment compositions are free or substantially free of amphoteric surfactants.

Fatty Compounds

Optionally, treatment compositions that can be used in methods according to the disclosure may include at least one fatty compound. In certain embodiments, the at least one fatty compound may be chosen from lower alkanes, fatty alcohols, fatty acids, esters of fatty acids, esters of fatty alcohols, oils such as mineral, vegetable, animal, silicone and non-silicone oils, silicone and non-silicone waxes, or combinations of any two or more thereof.

In some embodiments, treatment compositions include at least one fatty compound chosen from volatile and non-volatile silicone oils, which may optionally be amino functionalized. Non-limiting examples of silicone oils that can be used include dimethicone, amodimethicone, cyclomethicone, polysilicone-1 1 , phenyl trimethicone, trimethylsilylamodimethicone, and stearoxytrimethylsilane. For example, the treatment composition may comprise at least one silicone chosen from amodimethicone, PEG-7 Dimethicone, PEG- 8 Dimethicone, PEG-9 Dimethicone, PEG-10 Dimethicone, PEG-12 Dimethicone, PEG-14 Dimethicone, PEG-17 Dimethicone, PEG/PPG-3/10 Dimethicone, PEG/PPG-4/12 Dimethicone, PEG/PPG- 17/18 Dimethicone, cetyl PEG/PPG-10/1 dimethicone, Dimethicone PEG-8 Benzoate, Dimethicone PEG-7 Phosphate, Dimethicone PEG-8 Phosphate, Dimethicone PEG- 10 Phosphate, or a mixture of two or more thereof. In some preferred embodiments, the treatment compositions comprise a silicone oil component that comprises, consists essentially of, or consists of dimethicone, amodimethicone, or a mixture thereof.

As further examples, the silicone oil may be chosen from polydimethylsiloxanes (PDMSs), polydimethylsiloxanes comprising alkyl or alkoxy groups which are pendent and/or at the end of the silicone chain, which groups each contain from 2 to 24 carbon atoms, or phenyl silicones, such as phenyl trimethicones, phenyl dimethicones, phenyl(trimethylsiloxy)diphenylsiloxanes, diphenyl dimethicones, diphenyl(methyl-diphenyl)trisiloxanes, or (2-phenylethyl)trimethyl- siloxysilicates.

In some embodiments, treatment compositions include at least one fatty compound chosen from fatty alcohols. In certain embodiments, “fatty alcohol” refers to any alcohol with a carbon chain of C5 or greater, such as, for example, C8 or greater, C10 or greater, or C12 or greater, such as from 6 to 30 carbon atoms or from 8 to 30 carbon atoms. The fatty alcohols may be alkoxylated or non-alkoxylated, saturated or unsaturated, and linear or branched.

By way of example, fatty alcohols may be chosen from arachidyl alcohol, behenyl alcohol, caprylic alcohol, cetearyl alcohol, cetyl alcohol, coconut alcohol, decyl alcohol, hydrogenated tallow alcohol, jojoba alcohol, lauryl alcohol, myristyl alcohol, oleyl alcohol, palm alcohol, palm kernel alcohol, stearyl alcohol, tallow alcohol, tridecyl alcohol, or combinations of two or more thereof. In some preferred embodiments, the treatment compositions comprise a fatty alcohol component that comprises, consists essentially of, or consists of cetyl alcohol, stearyl alcohol, cetearyl alcohol, or mixtures thereof.

Useful and non-limiting fatty acids may be straight or branched chain acids and/or may be saturated or unsaturated. Non-limiting examples of fatty acids include diacids, triacids, and other multiple acids as well as salts of these fatty acids. For example, the fatty acid may optionally include or be chosen from lauric acid, palmitic acid, stearic acid, behenic acid, arichidonic acid, oleic acid, isostearic acid, sebacic acid, or combinations thereof. In some embodiments, fatty acid esters or fatty alcohol esters may be chosen. For example, esters of saturated or unsaturated, linear or branched C1 -C26 aliphatic mono- or polyacids and of saturated or unsaturated, linear or branched C1 - C26 aliphatic mono- or polyalcohols, the total carbon number of the esters more particularly being greater than or equal to 10 may be used. In other embodiments, esters of C4-C22 dicarboxylic or tricarboxylic acids and of C1 -C22 alcohols and esters of mono-, di- or tricarboxylic acids and of C2-C26 di-, tri-, tetra-, or pentahydroxy alcohols may also be used. As non-limiting examples, isostearyl lactate, lauryl lactate, linoleyl lactate, oleyl lactate, (iso)stearyl octanoate, isocetyl octanoate, octyl octanoate, cetyl octanoate, decyl oleate, isocetyl isostearate, isocetyl laurate, isocetyl stearate, isodecyl octanoate, isodecyl oleate, isononyl isononanoate, isostearyl palmitate, methyl acetyl ricinoleate, myristyl stearate, octyl isononanoate, 2-ethylhexyl isononanoate, octyl palmitate, octyl pelargonate, octyl stearate, octyldodecyl erucate, oleyl erucate, ethyl and isopropyl palmitates, 2-ethylhexyl palmitate, 2-octyldecyl palmitate, alkyl myristates such as isopropyl, butyl, cetyl, 2-octyldodecyl, myristyl or stearyl myristate, hexyl stearate, butyl stearate, isobutyl stearate, dioctyl malate, hexyl laurate, 2-hexyldecyl laurate, diethyl sebacate, diisopropyl sebacate, diisopropyl adipate, di-n-propyl adipate, dioctyl adipate, diisostearyl adipate, dioctyl maleate, glyceryl undecylenate, octyldodecyl stearoyl stearate, pentaerythrityl monoricinoleate, pentaerythrityl tetraisononanoate, pentaerythrityl tetrapelargonate, pentaerythrityl tetraisostearate, pentaerythrityl tetraoctanoate, propylene glycol dicaprylate, propylene glycol dicaprate, tridecyl erucate, triisopropyl citrate, triisostearyl citrate, glyceryl trilactate, glyceryl trioctanoate, trioctyldodecyl citrate, trioleyl citrate, propylene glycol dioctanoate, neopentyl glycol diheptanoate, diethylene glycol diisononanoate, and/or polyethylene glycol distearates may be chosen. In a preferred embodiment, the composition comprises at least one fatty acid ester and/or fatty alcohol ester, for example pentaerythrityl tetraisostearate.

In some embodiments, treatment compositions comprise at least one wax. Non-limiting examples of waxes that can be used include beeswax, hydrogenated alkyl olive esters, carnauba wax, candelilla wax, ouricoury wax, Japan wax, cork fibre wax or sugar cane wax, rice wax, rice bran wax, montan wax, paraffin wax, lignite wax or microcrystalline wax, ceresin or ozokerite, palm kernel glycerides/hydrogenated palm glycerides, palm butter, sumac wax, citrus aurantium dulcis (orange) peel wax, theobroma grandiflorum seed butter, helianthus annuus (sunflower) seed wax, siliconyl candellila wax, Chinese wax, cetyl palmitate, lanolin, shellac, spermaceti, cetyl esters, hydrogenated castor wax; triglyceride esters such as tribehenin (glyceryl tribehenate); synthetic waxes such as those of the hydrocarbon type and polyethylene waxes obtained from the polymerization or copolymerization of ethylene, polypropylene waxes, or mixtures of two or more of any of these waxes. In some preferred embodiments, the treatment compositions comprise a wax component that comprises, consists essentially of, or consists of cetyl esters.

In some embodiments, the treatment composition comprises one or more fatty compounds chosen from oils of animal, vegetable, or mineral origin (e.g. lanolin, squalene, fish oil, perhydrosqualene, mink oil, turtle oil, soybean oil, grape seed oil, sesame oil, maize oil, rapeseed oil, sunflower oil, cottonseed oil, avocado oil, olive oil, castor seed oil, jojoba seed oil, peanut oil, sweet almond oil, palm oil, cucumber oil, hazelnut oil, apricot kernel oil, wheat germ oil, calophyllum oil, macadamia oil, coconut oil, cereal germ oil, candlenut oil, thistle oil, candelilla oil, safflower oil, or shea butter), linear or branched hydrocarbons (e.g. polybutene, hydrogenated polyisobutene, polyisoprene, polydecenes such as hydrogenated polydecene, or also linear, branched and/or cyclic alkanes which are optionally volatile, such as, for example, isohexadecane, isododecane, isodecane, or isohexadecane), mono- and/or polyesters of fatty acids and/or of fatty alcohols (e.g. mono- and polyesters of hydroxy acids and of fatty alcohols, esters of benzoic acid and of fatty alcohols, polyesters of polyols, dipentaerythrityl C5-C9 esters, trimethylolpropane polyesters, propylene glycol polyesters, or polyesters of hydrogenated castor oil), perfluorinated and/or organofluorinated oils, fluorosilicone oils, or mixtures of two or more thereof. Nonlimiting examples of fatty acids that may be used include optionally branched and/or unsaturated fatty acids such as myristic acid, palmitic acid, stearic acid, behenic acid, oleic acid, linoleic acid, linolenic acid, isostearic acid, or mixtures of two or more thereof.

If present, the total amount of fatty compounds in the treatment composition may range from about 0.1 % to about 20%, such as from about 1 % to about 20%, from about 2% to about 15%, from about 3% to about 12%, or from about 5% to about 10% by weight, relative to the total weight of the composition. In some preferred embodiments, the treatment compositions comprise at least one fatty compound chosen from silicone oils, fatty alcohols, waxes, or combinations thereof, where the total amount of fatty compounds in the composition ranges from about 1 % to about 20%, preferably from about 2% to about 15%, more preferably from about 3% to about 12%, and most preferably from about 5% to about 10% by weight, relative to the total weight of the composition.

Thickening Agents

Treatment compositions that can be used in methods according to the disclosure optionally comprise at least one thickening agent. Useful thickening agents include, but are not limited to, semisynthetic polymers, such as semisynthetic cellulose derivatives, synthetic polymers, such as carbomers, poloxamers, and acrylates/beheneth-25 methacrylate copolymer, acrylates copolymer, polyethyleneimines (e.g., PEI-10), naturally occurring polymers, such as acacia, tragacanth, alginates (e.g., sodium alginate), carrageenan, vegetable gums, such as xanthan gum, guar gum, petroleum jelly, waxes, particulate associate colloids, such as bentonite, colloidal silicon dioxide, and microcrystalline cellulose, celluloses such as hydroxyethylcellulose and hydroxypropylcellulose, and guars such as hydroxypropyl guar.

In some embodiments, the thickening agent may be chosen from associative thickening polymers such as anionic associative polymers, amphoteric associative polymers, cationic associative polymers, or nonionic associative polymers. A non-limiting example of an amphoteric associative polymer is acrylates/beheneth-25 methacrylate copolymer, and non-limiting examples of anionic associative polymers include acrylates copolymer and acrylates crosspolymer-4.

If present, the total amount of thickening agents may range from about 0.01 % to about 8%, such as from about 0.05% to about 5%, from about 0.1 % to about 4%, from about 0.2% to about 3%, or from about 0.3% to about 2% by weight, relative to the total weight of the composition.

Auxiliary Components

Treatment compositions that can be used in methods according to the disclosure may optionally include one or more auxiliary components. Non-limiting examples include preservatives, fragrances, pH adjusters, salts, antioxidants, vitamins, vitamin derivatives, ceramides, botanical extracts, proteins, protein hydrolysates, protein isolates, hydrotropes, pearlescent agents, buffers, sequestering agents, pigments, dyes (e.g. natural and/or synthetic direct dyes), and the like.

The total amount of auxiliary components, if present, typically ranges from about 0.01 % to about 10% based on the total weight of the treatment composition. For example, in some embodiments the individual amounts of each component or the total amount of components may range from about 0.1 % to about 10%, about 0.1 % to about 8%, about 0.1 % to about 5%, about 0.1 % to about 4%, about 0.1 % to about 3%, about 0.1 % to about 2%, about 1 % to about 10%, about 1 % to about 8%, about 1 % to about 5%, about 1 % to about 4%, about 1 % to about 3%, or about 1 % to about 2% by weight, based on the total weight of the treatment composition.

Treatment compositions that can be used in methods according to the disclosure typically have a pH of less than or equal to 7, such as less than or equal to about 6, less than or equal to about 5, less than or equal to about 4.5, or less than or equal to about 4. For example, the treatment compositions may have a pH ranging from about 1 to about 7, such as from about 2 to about 6, from about 2.5 to about 5.5, from about 2.5 to about 5, from about 2.5 to about 4.5, or from about 3 to about 4. In some embodiments, the pH of the composition may be, for example, about 3, about 3.25, about 3.5, about 3.75, or about 4, including all ranges and subranges thereof.

The treatment compositions may be in any suitable form. For example, suitable treatment compositions may be in the form of a liquid, a gel, a gel cream, a high-, medium- or low-density cream, a serum, a lotion, etc.

II. DYEING COMPOSITIONS

Compositions and methods for dyeing hair are well known. It is contemplated that treatment compositions described herein can advantageously be used in connection with a permanent (oxidative) dye process. Typically, an oxidative dye composition is prepared at or near the time of use by mixing a dye base composition comprising oxidative dye compounds with an oxidizing composition, the resulting mixture (the oxidative dye composition) applied to the hair as desired, left to process for a period of time, which may, for example, range from about 10 minutes to about an hour, and then the oxidative dye composition is rinsed from the hair.

Oxidative dye compounds that can be used include oxidation bases which may be optionally combined with one or more couplers. By way of example, the oxidation bases may be chosen from para-phenylenediamines, bis(phenyl)alkylenediamines, para-aminophenols, ortho-aminophenols and heterocyclic bases, and the addition salts thereof.

Among the para-phenylenediamines that may be mentioned, for example, are para-phenylenediamine, para-toluenediamine, 2-chloro-para- phenylenediamine, 2,3-dimethyl-para-phenylenediamine, 2,6-dimethyl-para- phenylenediamine, 2,6-diethyl-para-phenylenediamine, 2,5-dimethyl-para- phenylenediamine, N,N-dimethyl-para-phenylenediamine, , N,N-diethyl-para- phenylenediamine, N,N-dipropyl-para-phenylenediamine, 4-amino-N,N-diethyl-3- methylaniline, N,N-bis(p-hydroxyethyl)-para-phenylenediamine, 4-N,N-bis(p- hydroxyethyl)amino-2-methylaniline, 4-N,N-bis(p-hydroxyethyl)amino-2-chloroaniline, 2-p-hydroxyethyl-para-phenylenediamine, 2-methoxymethyl-para-phenylenediamine, 2-fluoro-para-phenylenediamine, 2-isopropyl-para-phenylenediamine, N-(p- hydroxypropyl)-para-phenylenediamine, 2-hydroxymethyl-para-phenylenediamine, N,N-dimethyl-3-methyl-para-phenylenediamine, N-ethyl-N-(p-hydroxyethyl)-para- phenylenediamine, N-(P,y-dihydroxypropyl)-para-phenylenediamine, N-(4'- aminophenyl)-para-phenylenediamine, N-phenyl-para-phenylenediamine, 2-p- hydroxyethyloxy-para-phenylenediamine, 2-p-acetylaminoethyloxy-para- phenylenediamine, N-(p-methoxyethyl)-para-phenylenediamine, 4- aminophenylpyrrolidine, 2-thienyl-para-phenylenediamine, 2-p-hydroxyethylamino-5- aminotoluene and 3-hydroxy-1 -(4'-aminophenyl)pyrrolidine, and the addition salts thereof with an acid.

Among the para-phenylenediamines mentioned above, paraphenylenediamine, para-toluenediamine, 2-isopropyl-para-phenylenediamine, 2-p- hydroxyethyl-para-phenylenediamine, 2-p-hydroxyethyloxy-para-phenylenediamine, 2,6-dimethyl-para-phenylenediamine, 2,6-diethyl-para-phenylenediamine, 2,3- dimethyl-para-phenylenediamine, N,N-bis(p-hydroxyethyl)-para-phenylenediamine, 2- chloro-para-phenylenediamine and 2-p-acetylaminoethyloxy-para-phenylenediamine, and the addition salts thereof with an acid, are particularly preferred. Among the bis(phenyl)alkylenediamines that may be mentioned, for example, are N,N'-bis(p-hydroxyethyl)-N,N'-bis(4'-aminophenyl)-1 ,3-diaminopropanol, N,N'-bis(p-hydroxyethyl)-N,N'-bis(4'-aminophenyl)ethylenediamine, N,N'-bis(4- aminophenyl)tetramethylenediamine, N,N'-bis(p-hydroxyethyl)-N,N'-bis(4- aminophenyl)tetramethylenediamine, N,N'-bis(4- methylaminophenyl)tetramethylenediamine, N,N'-bis(ethyl)-N,N'-bis(4'-amino-3'- methylphenyl)ethylenediamine and 1 ,8-bis(2,5-diaminophenoxy)-3,6-dioxaoctane, and the addition salts thereof.

Among the para-aminophenols that may be mentioned, for example, are para-aminophenol, 4-amino-3-methylphenol, 4-amino-3-fluorophenol, 4-amino-3- chlorophenol, 4-amino-3-hydroxymethylphenol, 4-amino-2-methylphenol, 4-amino-2- hydroxymethylphenol, 4-amino-2-methoxymethylphenol, 4-amino-2- aminomethylphenol, 4-amino-2-(p-hydroxyethylaminomethyl)phenol and 4-amino-2- fluorophenol, and the addition salts thereof with an acid.

Among the ortho-aminophenols that may be mentioned, for example, are 2-aminophenol, 2-amino-5-methylphenol, 2-amino-6-methylphenol and 5-acetamido-

2-aminophenol, and the addition salts thereof.

Among the heterocyclic bases that may be mentioned, for example, are pyridine derivatives, pyrimidine derivatives and pyrazole derivatives.

Among the pyridine derivatives that may be mentioned are 2,5- diaminopyridine, 2-(4-methoxyphenyl)amino-3-aminopyridine and 3,4- diaminopyridine, and the addition salts thereof.

Other pyridine oxidation bases can include the 3-aminopyrazolo[1 ,5- a]pyridine oxidation bases or the addition salts thereof described, for example pyrazolo[1 ,5-a]pyrid-3-ylamine, 2-acetylaminopyrazolo[1 ,5-a]pyrid-3-ylamine, 2- morpholin-4-ylpyrazolo[1 ,5-a]pyrid-3-ylamine, 3-aminopyrazolo[1 ,5-a]pyridine-2- carboxylic acid, 2-methoxypyrazolo[1 ,5-a]pyrid-3-ylamine, (3-aminopyrazolo[1 ,5- a]pyrid-7-yl)methanol, 2-(3-aminopyrazolo[1 ,5-a]pyrid-5-yl)ethanol, 2-(3- aminopyrazolo[1 ,5-a]pyrid-7-yl)ethanol, (3-aminopyrazolo[1 ,5-a]pyrid-2-yl)methanol, 3,6-diaminopyrazolo[1 ,5-a]pyridine, 3,4-diaminopyrazolo[1 ,5-a]pyridine, pyrazolo[1 ,5- a]pyridine-3,7-diamine, 7-morpholin-4-ylpyrazolo[1 ,5-a]pyrid-3-ylamine, pyrazolo[1 ,5- a]pyridine-3,5-diamine, 5-morpholin-4-ylpyrazolo[1 ,5-a]pyrid-3-ylamine, 2-[(3- aminopyrazolo[1 ,5-a]pyrid-5-yl)(2-hydroxyethyl)amino]ethanol, 2-[(3- aminopyrazolo[1 ,5-a]pyrid-7-yl)(2-hydroxyethyl)amino]ethanol, 3-aminopyrazolo[1 ,5- a]pyridin-5-ol, 3-aminopyrazolo[1 ,5-a]pyridin-4-ol , 3-aminopyrazolo[1 ,5-a]pyridin-6-ol,

3-aminopyrazolo[1 ,5-a] pyridin-7-ol , 2-p-hydroxyethoxy-3-amino-pyrazolo[1 ,5- a]pyridine; 2-(4-dimethylpyperazinium-1 -yl)-3-amino-pyrazolo[1 ,5-a]pyridine; and the addition salts thereof.

More particularly, oxidation bases can be selected from 3- aminopyrazolo-[1 ,5-a]-pyridines and preferably substituted on carbon atom 2 by: one (di)(C1 -C6)(alkyl)amino group wherein said alkyl group can be substituted by at least one hydroxy, amino, imidazolium group; one heterocycloalkyl group containing from 5 to 7 members chain, and from 1 to 3 heteroatomes, potentially cationic, potentially substituted by one or more (C1 -C6)alkyl, such as di(C1 -C4)alkylpiperazinium; or one (C1 -C6)alkoxy potentially substituted by one or more hydroxy groups such as a- hydroxyalkoxy, and the addition salts thereof.

Among the pyrimidine derivatives that may be mentioned are the compounds such as 2,4,5,6-tetraaminopyrimidine, 4-hydroxy-2,5,6-triaminopyrimidine,

2-hydroxy-4,5,6-triaminopyrimidine, 2,4-dihydroxy-5,6-diaminopyrimidine, 2,5,6- triaminopyrimidine and their addition salts and their tautomeric forms, when a tautomeric equilibrium exists.

Among the pyrazole derivatives that may be mentioned are the compounds such as 4,5-diamino-1 -methylpyrazole, 4,5-diamino-1 -(p- hydroxyethyl)pyrazole, 3,4-diaminopyrazole, 4,5-diamino-1 -(4'-chlorobenzyl)pyrazole,

4.5-diamino-1 ,3-dimethylpyrazole, 4,5-diamino-3-methyl-1 -phenylpyrazole, 4,5- diamino-1 -methyl-3-phenylpyrazole, 4-amino-1 ,3-dimethyl-5-hydrazinopyrazole, 1 - benzyl-4,5-diamino-3-methylpyrazole, 4,5-diamino-3-tert-butyl-1 -methylpyrazole, 4,5- diamino-1 -tert-butyl-3-methylpyrazole, 4,5-diamino-1 -(p-hydroxyethyl)-3- methylpyrazole, 4,5-diamino-1 -ethyl-3-methylpyrazole, 4,5-diamino-1 -ethyl-3-(4'- methoxyphenyl)pyrazole, 4,5-diamino-1 -ethyl-3-hydroxymethylpyrazole, 4,5-diamino-

3-hydroxymethyl-1 -methylpyrazole, 4,5-diamino-3-hydroxymethyl-1 -isopropyl- pyrazole, 4,5-diamino-3-methyl-1 -isopropylpyrazole, 4-amino-5-(2'-aminoethyl)amino- 1 ,3-dimethylpyrazole, 3,4,5-triaminopyrazole, 1 -methyl-3,4,5-triaminopyrazole, 3,5- diamino-1 -methyl-4-methylaminopyrazole, 3,5-diamino-4-(p-hydroxyethyl)amino-1 - methyl-pyrazole, and the addition salts thereof. 4,5-diamino-1 -(- methoxyethyl)pyrazole may also be used.

Pyrazole derivatives that may also be mentioned include diamino-N,N- dihydro-pyrazolopyrazolones, such as the following compounds and the addition salts thereof: 2,3-diamino-6,7-dihydro-1 H,5H-pyrazolo[1 ,2-a]pyrazol-1 -one, 2-amino-3- ethylamino-6,7-dihydro-1 H,5H-pyrazolo[1 ,2-a]pyrazol-1 -one, 2-amino-3- isopropylamino-6,7-dihydro-1 H,5H-pyrazolo[1 ,2-a]pyrazol-1 -one, 2-amino-3- (pyrrolidi n- 1 -yl)-6,7-dihydro-1 H,5H-pyrazolo[1 ,2-a]pyrazol-1 -one, 4,5-diamino-1 ,2- dimethyl-1 ,2-dihydropyrazol-3-one, 4,5-diamino-1 ,2-diethyl-1 ,2-dihydropyrazol-3-one,

4.5-diamino-1 ,2-di-(2-hydroxyethyl)-1 ,2-dihydropyrazol-3-one, 2-amino-3-(2- hydroxyethyl)amino-6,7-dihydro-1 H,5H-pyrazolo[1 ,2-a]pyrazol-1 -one, 2-amino-3- dimethylamino-6,7-dihydro-1 H,5H-pyrazolo[1 ,2-a]pyrazol-1 -one, 2,3-diamino-5,6,7,8- tetrahydro-1 H,6H-pyridazino[1 ,2-a]pyrazol-1 -one, 4-amino-1 ,2-diethyl-5-(pyrrolidin- 1 - yl)-1 ,2-dihydropyrazol-3-one, 4-amino-5-(3-dimethylaminopyrrolidin-1 -yl)-1 ,2-diethyl- 1 ,2-dihydropyrazol-3-one, 2,3-diamino-6-hydroxy-6,7-dihydro-1 H,5H-pyrazolo[1 ,2- a]pyrazol-1 -one.

4,5-diamino-1 -(-hydroxyethyl)pyrazole and/or 2,3-diamino-6,7-dihydro- 1 H,5H-pyrazolo[1 ,2-a]pyrazol-1 -one and/or a salt thereof can be used as heterocyclic bases.

Dyeing compositions that can be used may optionally further comprise one or more couplers. Among these couplers, mention may be made especially of meta-phenylenediamines, meta-aminophenols, meta-diphenols, naphthalene-based couplers and heterocyclic couplers, and also the addition salts thereof.

Mention may be made, for example, of 2-methyl-5-aminophenol, 5-N-(B- hydroxyethyl)amino-2-methylphenol, 3-aminophenol, 5-amino-6-chloro-o-cresol (3- amino-2-chloro-6-methylphenol), 1 ,3-dihydroxybenzene, 1 ,3-dihydroxy-2- methylbenzene, 4-chloro-1 ,3-dihydroxybenzene, 2,4-diamino-1 -(B- hydroxyethyloxy)benzene, 2-amino-4-(B-hydroxyethylamino)-1 -methoxybenzene, 1 ,3- diaminobenzene, 1 ,3-bis(2,4-diamino-phenoxy)propane, 3-ureidoaniline, 3-ureido-1 - dimethylaminobenzene, sesamol, 1 -B-hydroxyethylamino-3,4- methylenedioxybenzene, a-naphthol, 2-methyl-1 -naphthol, 6-hydroxyindole, 4- hydroxyindole, 4-hydroxy-N-methylindole, 2-amino-3-hydroxypyridine, 6- hydroxybenzomorpholine, 3,5-diamino-2,6-dimethoxypyridine, 1 -N-(B-hydroxyethyl)- amino-3,4-methylenedioxybenzene, 2,6-bis(B-hydroxyethylamino)toluene, 6-hydroxy- indoline, 2,6-dihydroxy-4-methylpyridine, 1 -H-3-methylpyrazol-5-one, 1 -phenyl-3- methyl-pyrazol-5-one, 2,6-dimethylpyrazolo[1 ,5-b]-1 ,2,4-triazole, 2,6-dimethyl[3,2-c]- 1 ,2,4-triazole, and 6-methylpyrazolo[1 ,5-a]benzimidazole, the addition salts thereof with an acid, and mixtures thereof.

In general, the addition salts of the oxidation bases and couplers that may be used in the context of the invention are especially selected from the addition salts with an acid such as the hydrochlorides, hydrobromides, sulfates, citrates, succinates, tartrates, lactates, tosylates, benzenesulfonates, phosphates, and acetates.

The oxidation base(s) may be present in a total amount ranging from about 0.001 % to about 10%, such as from about 0.001 % to about 5%, from about 0.001 % to about 3%, from about 0.001 % to about 2%, from about 0.001 % to about 1 %, from about 0.005% to about 5%, from about 0.005% to about 3%, from about 0.005% to about 2%, from about 0.005% to about 1 %, from about 0.01 % to about 5%, from about 0.01 % to about 3%, from about 0.01 % to about 2%, or from about 0.01 % to about 1 %, by weight, relative to the total weight of the oxidative dye base or oxidative dye composition. The coupler(s), if they are present, may be present in a total amount ranging from about 0.001 % to about 10%, such as from about 0.001 % to about 5%, from about 0.001 % to about 3%, from about 0.001 % to about 2%, from about 0.001% to about 1 %, from about 0.005% to about 5%, from about 0.005% to about 3%, from about 0.005% to about 2%, from about 0.005% to about 1 %, from about 0.01 % to about 5%, from about 0.01 % to about 3%, from about 0.01 % to about 2%, or from about 0.01 % to about 1 %, by weight, relative to the total weight of the oxidative dye base or oxidative dye composition.

Prior to applying the oxidative dye base composition to the hair, it is generally mixed with an oxidizing composition comprising at least one oxidizing agent and a cosmetically suitable carrier, for example water. Typically, oxidizing compositions can comprise additional components, such as, for example, rheologymodifying agents, chelants, fatty substances, ceramides, pH adjusting agents, amino acids, carboxylic acids, preservatives, fragrances, surfactants, etc. The oxidizing agent can be, for example, hydrogen peroxide, urea peroxide, alkali metal bromates, alkali metal ferricyanides, or persalts, such as perborates or persulphates. The total amount of oxidizing agent and carrier can vary depending on the desired strength of the oxidizing composition. For example, the total amount of oxidizing agent may be from about 1 % to about 40%, such as from about 1 % to about 30%, about 1 % to about 20%, about 1 % to about 15%, about 1 % to about 12%, about 3% to about 20%, about 3% to about 15%, about 3% to about 12%, about 5% to about 20%, about 5% to about 15%, about 5% to about 12%, about 7% to about 20%, about 7% to about 15%, about 7% to about 12%, about 9% to about 20%, about 9% to about 15%, or about 9% to about 12% by weight, based on the total weight of the oxidizing composition. In some cases, the oxidizing composition is aqueous and the oxidizing agent comprises, consists essentially of, or consists of hydrogen peroxide. For example, the hydrogen peroxide may be present in an amount ranging from about 5% to about 20%, such as about 7% to about 15%, about 8% to about 13%, about 8% to about 10%, about 9% to about 13%, or about 10% to about 12%, for example about 7%, about 8%, about 9% about 10%, about 1 1 %, about 12%, about 13%, about 14%, or about 15% by weight, based on the total weight of the oxidizing composition. The oxidizing composition may be, for instance, 20V, 30V, or 40V hydrogen peroxide compositions. The oxidative dye base composition is typically mixed with an oxidizing composition at a ratio ranging from about 1 :5 to about 5:1 , such as from about 1 :4 to about 4:1 , about 1 :3 to about 3:1 , or about 1 :2 to about 2:1 , or is, for example, about 5:1 , about 4:1 , about 3:1 , about 2:1 , about 1 .5:1 , about 1 :1 , about 1 :1 .5, about 1 :2, about 1 :3, about 1 :4, or about 1 :5, generally at or near the time of use, to form the oxidative hair dye composition. The mixture is generally alkaline, having a pH of greater than about 7, such as greater than about 8, greater than about 9, or greater than about 10, for example ranging from about 7 to about 10.5, or from about 7.5 to about 10. Typically, once the mixture is prepared it is applied to hair that may be wet, damp, or dry, optionally covered (e.g. with foil), optionally heated (e.g. with a blow dryer or hood dryer), and after a processing time sufficient to achieve the desired color, the hair is rinsed.

Although the foregoing oxidative dye base compositions, oxidizing compositions, and processes for dyeing hair are disclosed for use in the methods according to the disclosure, those skilled in the art will appreciate that variations of hair dyeing compositions and processes can also be used. Thus, it is not intended that the foregoing dyeing compositions and processes are limiting of methods according to the disclosure.

III. METHODS OF TREATING KERATIN FIBERS

The disclosure relates to methods of treating keratin fibers with a treatment composition according to the disclosure in connection with a process for dyeing hair. The methods comprise applying a treatment composition onto the hair, optionally leaving the composition on the hair for a period of time (“processing time,” “resting period,” or “leave-in period”), and optionally rinsing the composition from the hair. The treatment composition can be applied to the hair before and/or after a hair dye composition is applied to the hair, or may be applied to the hair simultaneously with a hair dye composition.

Although not required, methods according to the disclosure may also include a step of heating the hair to which the treatment composition has been applied, for example during the resting period while the treatment composition is on the hair. For example, a blow dryer, hood dryer, etc., may be used.

The period of time which the treatment composition is left on the hair may last for an amount of time appropriate to allow the active agents to provide benefits to the keratin fibers, such as about 30 seconds, about 1 minute, about 2 minutes, about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 30 minutes, about 45 minutes, about 1 hour, about 2 hours, etc., or may range from a period of time using any of the foregoing as upper and lower limits. By way of non-limiting example, the leave-in period may range from about 30 seconds to about 60 minutes, from about 30 seconds to about 45 minutes, from about 30 seconds to about 30 minutes, from about 30 seconds to about 20 minutes, from about 30 seconds to about

15 minutes, from about 30 seconds to about 10 minutes, from about 30 seconds to about 5 minutes, from about 1 minute to about 60 minutes, from about 1 minute to about 45 minutes, from about 1 minute to about 30 minutes, from about 1 minute to about 20 minutes, from about 1 minute to about 15 minutes, from about 1 minute to about 10 minutes, from about 1 minute to about 5 minutes, from about 2 minutes to about 60 minutes, from about 2 minutes to about 45 minutes, from about 2 minutes to about 30 minutes, from about 2 minutes to about 20 minutes, from about 2 minutes to about 15 minutes, from about 2 minutes to about 10 minutes, from about 2 minutes to about 5 minutes, etc.

The period of time which the dye composition is left on the hair may last for an amount of time appropriate to allow the desired color to be achieved, which may range from about 1 minute to about 60 minutes, such as from about 3 minutes to about 45 minutes, from about 5 minutes to about 30 minutes, or from about 10 minutes to about 20 minutes.

In exemplary embodiments, a treatment composition according to the disclosure can be applied to hair before, during, and/or after a dye composition is applied to the hair, with or without intermediate rinsing. For example, one such method may include applying a treatment composition according to the disclosure to wet, damp, or dry hair, leaving the composition on the hair for a suitable processing time, optionally rinsing the hair, and then substantially immediately thereafter (i.e. within the same hair dyeing process), with or without intermediate rinsing of the hair, applying a dye composition to the hair. Another exemplary method may include applying a dye composition to the hair, and substantially immediately thereafter (i.e. within the same hair dyeing process), with or without intermediate rinsing of the hair, applying a treatment composition according to the disclosure to the hair. In either of the foregoing exemplary embodiments, the treatment composition and dye composition may optionally be layered on top of one another on the hair (no rinsing), or may optionally be applied to the hair in alternating layers (rinsing) during the hair dyeing process. As yet a further exemplary method, a treatment composition according to the disclosure may be added to or mixed with a composition for dyeing the hair, for example an oxidative dye base composition, an oxidizing composition, or a mixture thereof, at or near the time of use. In a still further exemplary method, a treatment composition and a dye composition may be applied to the hair simultaneously, for example by means of a dual-chamber applicator that is configured to dispense two compositions at the same time. Thus, it is contemplated that treatment compositions according to the disclosure may be incorporated into a hair dyeing process, thereby reducing, minimizing, or preventing damage to the hair that would otherwise be expected to result from such harsh chemical treatments.

As a non-limiting example of hair dyeing methods according to the disclosure, a treatment composition as described herein may be applied to wet, damp, or dry hair, left to process for a leave-in time as described herein, for example ranging from about one minute to about two hours such as from about five minutes to about one hour, optionally with heating. The hair may then be rinsed, followed by application of a hair dyeing composition according to conventional hair dyeing routines. As a further non-limiting example of hair dyeing methods according to the disclosure, a treatment composition as described herein may be applied to wet, damp, or dry hair, left to process for a leave-in time as described herein, for example ranging from about one minute to about two hours such as from about five minutes to about one hour, optionally with heating. Without rinsing the treatment composition from the hair, a dyeing composition may be applied to the hair and the hair dyeing process followed according to conventional hair dyeing routines.

As another non-limiting example of hair dyeing methods according to the disclosure, a hair dyeing composition may be applied to the hair in order to dye the hair according to conventional dyeing routines. The hair may then be rinsed, followed by application of a treatment composition as described herein to wet, damp, or dry hair, left to process for a leave-in time as described herein, for example ranging from about one minute to about two hours such as from about five minutes to about one hour, optionally with heating. The hair may then be subsequently rinsed. As yet another non-limiting example of hair dyeing methods according to the disclosure, a hair dye composition may be applied to the hair according to conventional hair dyeing routines. Without rinsing the dye composition from the hair, a treatment composition as described herein may be applied to wet, damp, or dry hair, left to process for a leave- in time as described herein, for example ranging from about one minute to about two hours such as from about five minutes to about one hour, optionally with heating. The hair may then be subsequently rinsed.

Surprisingly, hair that has been treated with treatment compositions and methods according to the disclosure before, during, and/or after the dyeing process has less damage than dyed hair not treated with treatment compositions and methods according to the disclosure before, during, and/or after the dyeing process. The hair may have lower elasticity and/or greater tensile strength than hair similarly dyed but not treated according to the disclosure. Thus, additional methods according to the disclosure include methods for reducing or minimizing hair damage in a process for dyeing hair, methods for preventing hair damage from a process for dyeing hair, and methods for improving elasticity and/or tensile strength of hair in a process for dyeing hair.

Having described the many embodiments of the present invention in detail, it will be apparent that modifications and variations are possible without departing from the scope of the disclosure defined in the appended claims. Furthermore, it should be appreciated that all examples in the present disclosure, while illustrating many embodiments of the disclosure, are provided as non-limiting examples and are, therefore, not to be taken as limiting the various aspects so illustrated. It is to be understood that all definitions herein are provided for the present disclosure only.

As used herein, treating hair with a treatment composition or applying a treatment composition to hair that is “in connection with a process for dyeing hair,” “within the same hair dyeing process,” and variations thereof, are intended to convey that the treatment composition is applied to the hair within close proximity of time as the hair is subjected to a process for dyeing the hair, such that a person of skill in the art would consider the processes of treating hair with a treatment composition as described herein and dyeing the hair to be a single process. For example, the treatment composition may be applied to the hair less than 24 hours, such as less than 12 hours, less than 6 hours, less than 4 hours, less than 3 hours, less than 2 hours, less than 1 hour, less than 45 minutes, less than 30 minutes, or less than 15 minutes before and/or after a hair dye composition is applied to the hair.

In this application, the use of the singular includes the plural unless specifically stated otherwise. The singular forms “a,” “an,” “the,” and “at least one” are understood to encompass the plural as well as the singular unless the context clearly dictates otherwise. The expression “one or more” means “at least one” and thus includes individual components as well as mixtures/combinations. Likewise, the term “a salt thereof” also relates to “salts thereof.” Thus, where the disclosure refers to “an element selected from the group consisting of A, B, C, D, E, F, a salt thereof, or mixtures thereof,” it indicates that that one or more of A, B, C, D, and F may be included, one or more of a salt of A, a salt of B, a salt of C, a salt of D, a salt of E, or a salt of F may be included, or a mixture of any two of A, B, C, D, E, F, a salt of A, a salt of B, a salt of C, a salt of D, a salt of E, and a salt of F may be included.

The term “and/or” should be understood to include both the conjunctive and the disjunctive. For example, “amino acids and/or salts thereof” means “amino acids and salts thereof” as well as “amino acids or salts thereof,” and expressly covers instances of either.

As used herein, the term “salts” referred to throughout the disclosure may include salts having a counterion such as an alkali metal, alkaline earth metal, or ammonium counterion. This list of counterions, however, is non-limiting. Salts also include a dissociated form of a compound, e.g. in an aqueous solution.

As used herein, the phrases “and mixtures thereof,” “and mixtures of two or more thereof,” “and a mixture thereof,” “and combinations thereof,” “and a combination thereof,” and combinations of two or more thereof,” “and a combination of two or more thereof,” “or mixtures thereof,” “or a mixture thereof,” “or combinations thereof,” “or combinations of two or more thereof,” “or a combination thereof,” and the like are used interchangeably to denote that the listing of components immediately preceding the phrase, such as “A, B, C, D, or mixtures thereof” signify that the component(s) may be chosen from A, from B, from C, from D, from A+B, from A+B+C, from A+D, from A+C+D, etc., without limitation on the variations thereof. Thus, the components may be used individually or in any combination thereof.

For purposes of the present disclosure, it should be noted that to provide a more concise description, some of the quantitative expressions given herein are not qualified with the term “about.” It is understood that whether the term “about” is used explicitly or not, every quantity given herein is meant to refer to the actual given value, and it is also meant to refer to the approximation to such given value that would reasonably be inferred based on the ordinary skill in the art, including approximations due to the experimental and/or measurement conditions for such given value, unless otherwise stated. All ranges and amounts given herein are intended to include sub-ranges and amounts using any disclosed point as an end point, and all endpoints are intended to be included unless expressly stated otherwise. Thus, a range of “1 % to 10%, such as 2% to 8%, such as 3% to 5%,” is intended to encompass ranges of “1 % to 8%,” “1 % to 5%,” “2% to 10%,” and so on. All numbers, amounts, ranges, etc., are intended to be modified by the term “about,” whether or not expressly stated, unless expressly stated otherwise. Similarly, a range given of “about 1 % to 10%” is intended to have the term “about” modifying both the 1 % and the 10% endpoints. The term “about” is used herein to indicate a difference of up to +/- 10% from the stated number, such as +/- 9%, +/- 8%, +/- 7%, +/- 6%, +/- 5%, +/- 4%, +/- 3%, +/- 2%, or +/- 1 %. Unless expressly stated otherwise, “about” means +/- 5%. Likewise, all endpoints of ranges are understood to be individually disclosed, such that, for example, a range of 1 :2 to 2:1 is understood to disclose a ratio of both 1 :2 and 2:1 .

As used herein, if a component is described as being present “in an amount up to” a certain amount, it is intended that such component is, in fact, present in the composition, i.e. is present in an amount greater than 0%.

All amounts given herein are relative to the amount of active material, unless otherwise indicated.

All percentages, parts and ratios herein are based upon the total weight of the compositions of the present disclosure, unless otherwise indicated.

As used herein, all ranges provided are meant to include every specific range within, and combination of sub ranges between, the given ranges. Thus, a range from 1 -5, includes specifically 1 , 2, 3, 4 and 5, as well as sub ranges such as 2-5, 3-5, 2-3, 2-4, 1 -4, etc.

In this application, the terms “keratin fibers” and “hair” are used interchangeably, without intending to be limiting. A person skilled in the art will understand that keratin fibers include hair, such as hair that grows from the scalp, which is frequently dyed in a cosmetic process for altering the appearance of the hair.

As used herein, the phrase “applying a composition onto hair” and variations thereof are intended to mean contacting the hair with at least one of the compositions described herein in any manner. It may also mean contacting the hair in an effective amount.

The term “treating hair” (and its grammatical variations) as used herein refers to the application of compositions as described herein onto the surface of hair. The term “treating hair” (and its grammatical variations) as used herein also refers to contacting hair with the compositions described herein.

Unless otherwise defined for any specific embodiment, the term “substantially free” or “essentially free” as used herein means that there is less than about 5% by weight of a specific material added to a composition, based on the total weight of the composition. For example, the compositions may include less than about 4%, less than about 3%, less than about 2%, less than about 1 .5%, less than about 1 %, less than about 0.5%, less than about 0.1 %, less than about 0.01%, less than about 0.001 %, or less than about 0.0001% of the specified material. As such, it is contemplated that any component described herein for use in the hair treatment compositions can be present in the compositions in amounts less than about 5%, less than about 4%, less than about 3%, less than about 2%, less than about 1 %, less than about 0.5%, less than about 0.1 %, less than about 0.01 %, less than about 0.001 %, or less than about 0.0001 %, and the composition will be considered “substantially free” of such material. A composition that is “free” of a component is understood to contain none of the specified component. However, it is understood that the terms “free” and “substantially free” refer to the amount of a component added to the composition, without including an amount of the component present in the composition as a minor component in a raw material. For example, a composition that is “free” of waxes may not have wax included as an intended component but may nevertheless contain a pigment that is coated with a wax, as such wax would be considered a minor component of the pigment material and would not be expected to provide benefits to the composition that would be expected by including a wax per se as an intended component.

Unless otherwise expressly stated, it is in no way intended that any method set forth herein be construed as requiring that its steps be performed in a specific order. Accordingly, where a method claim does not expressly recite an order to be followed by its steps or it is not specifically stated in the claims or descriptions that the steps are to be limited to a specific order, it not intended that any particular order be inferred.

The examples that follow serve to illustrate embodiments of the present disclosure without, however, being limiting in nature. It will be apparent to those skilled in the art that various modifications and variations can be made in the compositions and methods of the invention without departing from the spirit or scope of the invention. Thus, it is intended that the present disclosure covers the modifications and variations that come within the scope of the appended claims and their equivalents.

EXAMPLES

The following Examples are intended to be non-limiting and explanatory in nature only. In the Examples, amounts are expressed in percentage by weight (wt%) of active materials, relative to the total weight of the composition, unless otherwise indicated.

Example 1 - Treatment Compositions

Compositions 1 A-1 G, which can be used in methods according to according to the disclosure, were prepared as shown in Table 1. The pH of each of compositions 1 A-1 G was about 3.5.

TABLE 1

Compositions 1 A-1 G, which included a synergistic combination of components (carboxylic acids (citric and/or lactic acid), osmolytes (glycine betaine), and amino acids (arginine and/or serine)), can be used in methods according to the disclosure, for example can be applied to hair before and/or after a dyeing composition is applied to the hair, can be mixed with a dyeing composition, or can be applied to the hair simultaneously with a dyeing composition, and are expected to minimize, prevent, and/or repair damage to hair that would otherwise be expected from a hair dyeing process. The treatment compositions are also expected to improve elasticity and strength of the treated hair fibers.

Example 2 - Treatment Compositions Compositions 2A-2E, which can be used in methods according to according to the disclosure, were prepared as shown in Table 2.

TABLE 2

Compositions 2A-2E, which included a synergistic combination of components (carboxylic acids (citric acid), osmolytes (glycine betaine), and amino acids (arginine)), can be used in methods according to the disclosure, for example can be applied to hair before and/or after a dyeing composition is applied to the hair, can be mixed with a dyeing composition, or can be applied to the hair simultaneously with a dyeing composition, and are expected to minimize, prevent, and/or repair damage to hair that would otherwise be expected from a hair dyeing process. The treatment compositions are also expected to improve elasticity and strength of the treated hair fibers.

Example 3 - Treatment Compositions

Treatment compositions 3A-3D, which can be used in methods according to according to the disclosure, were prepared as shown in Table 3.

TABLE 3

Compositions 3A-3D, which included a synergistic combination of components (carboxylic acids (citric acid), osmolytes (glycine betaine), and amino acids (arginine)), can be used in methods according to the disclosure, for example can be applied to hair before and/or after a dyeing composition is applied to the hair, can be mixed with a dyeing composition, or can be applied to the hair simultaneously with a dyeing composition, and are expected to minimize, prevent, and/or repair damage to hair that would otherwise be expected from a hair dyeing process. The treatment compositions are also expected to improve elasticity and strength of the treated hair fibers.

Example 4 - Additional Treatment Compositions The following additional treatment compositions can also be prepared, and also are expected to similarly minimize, prevent, or repair damage to hair when used in connection with processes for dyeing the hair as described herein. The compositions are also expected to improve elasticity and strength of the treated hair fibers.

TABLE 4

Claims

SET OF CLAIMS

1 . A method for treating keratin fibers, the method comprising:

(i) applying to the keratin fibers a treatment composition comprising: a) at least one compound chosen from amino acids or salts thereof; b) at least one osmolyte; c) at least one compound chosen from carboxylic acids or salts thereof; and d) at least one solvent, and

(ii) applying to the keratin fibers a hair dye composition comprising at least one oxidative dye compound, wherein step (i) occurs before, during, and/or after step (ii).

2. The method of claim 1 , wherein the treatment composition comprises at least one osmolyte chosen from carbohydrate sugars, polyamines, betaines, or combinations of two or more thereof, preferably comprising at least one betaine chosen from compounds of formula (II) or salts thereof:

(R1 )(R2)(R3)m-A⁺-CR4R5-(X)_n-Y-

(H) wherein:

R1 , R2, and R3 are independently chosen from C1 -C4 alkyl groups;

A is N or S; m and n are independently 0 or 1 ;

X is a divalent C1 -C6 alkyl group, linear or branched, saturated or unsaturated, optionally substituted by one or more groups chosen from hydroxyl (-OH) or amino (-NH2); and

Y’ is -COO- or -OSO3-; with the provisos that: o when A is S, then m = 0 and R4 and R5 are independently chosen from a hydrogen atom or a saturated, unsaturated, linear, branched and/or cyclic (including aromatic and polycyclic chains), (C1 -C10) hydrocarbon chain, optionally interrupted by one or more heteroatoms or groups chosen from -S-, -N=, -NH-, or - C(NH)-, and/or optionally substituted by one or more groups chosen from hydroxyl (- OH), amino (-NH2), -SH, -COOH, or -CONH2; o when A is N and m = 0, R4 represents a hydrogen atom or a saturated, linear, or branched (C1 -C8)alkyl, and R5 forms, together with the nitrogen atom, a saturated heterocycle comprising from 5 to 8 ring members, optionally substituted by one or more groups chosen from hydroxyl or (C1 -C4)alkyl; and o when A is N and m = 1 , then R4 and R5 are independently chosen from a hydrogen atom or a saturated, unsaturated, linear, branched and/or cyclic (including aromatic and polycyclic chains) (C1 -C10) hydrocarbon chain, optionally interrupted by one or more heteroatoms or groups chosen from -S-, -N=, -NH-, or - C(NH)-, and/or optionally substituted by one or more groups chosen from hydroxyl (- OH), amino (-NH₂), -SH, -COOH, or -CONH₂.

3. The method of claim 1 or claim 2, wherein the treatment composition comprises at least one osmolyte chosen from carbohydrate sugars, preferably from C3-C6 monosaccharides, more preferably from pentoses, hexoses, derivatives thereof, or combinations of two or more thereof.

4. The method of any one of claims 1 to 3, wherein the treatment composition comprises at least one osmolyte chosen from polyamines, preferably chosen from diamines, triamines, tetramines, pentamines, or combinations of two or more thereof.

5. The method of any one of claims 1 to 4, wherein the treatment composition comprises at least one osmolyte chosen from compounds of formula (II), preferably chosen from zwitterionic amino acid derivatives bearing a quaternary ammonium group and comprising from 1 to 12 carbon atoms, preferably from 2 to 10 carbon atoms, more preferably from 3 to 8 carbon atoms.

6. The method of any one of claims 1 to 5, wherein the treatment composition comprises at least one osmolyte chosen from compounds of formula (II) chosen from valine betaine, glutamic acid betaine, glutamine betaine, trimethyl lysine, glycine betaine, histidine betaine, N-methyl histidine betaine, alanine betaine, betaalanine betaine, choline sulfate, pipecolic acid betaine, proline betaine, hydroxyproline betaine, tyrosine betaine, phenylalanine betaine, tryptophan betaine, leucine betaine, isoleucine betaine, salts thereof, or combinations of two or more thereof, preferably comprising glycine betaine.

7. The method of any one of claims 1 to 6, wherein the treatment composition comprises at least one compound of formula (II), wherein:

R1 and R2 are methyl; A is N; and/or

Y is COO-.

8. The method of any one of claims 1 to 7, wherein the total amount of osmolytes present in the treatment composition ranges from about 0.5% to about 10%, preferably from about 1 % to about 8%, more preferably from about 1 % to about 5%, most preferably from about 1 .5% to about 3.5% by weight, relative to the total weight of the composition.

9. The method of any one of claims 1 to 8, wherein the treatment composition comprises at least one amino acid of formula (I) or a salt thereof:

(I) wherein: p is an integer equal to 1 or 2, and when p = 1 , R forms, together with the nitrogen atom, a saturated heterocycle comprising from 5 to 8 ring members, preferably 5 ring members, optionally substituted by one or more groups chosen from hydroxyl or (C1 -C4)alkyl ; or when p = 2, R represents a hydrogen atom or a saturated, linear, or branched (C1 -C12)alkyl group, preferably a (C1 -C4)alkyl group, optionally interrupted by one or more heteroatoms or groups chosen from -S-, -NH-, or - C(NH)-, and/or optionally substituted by one or more groups chosen from hydroxyl (- OH), amino (-NH₂), -SH, -COOH,

-CONH2, — N H— C(N H)— N H2, or an imidazole ring.

10. The method of any one of claims 1 to 9, wherein the treatment composition comprises at least one amino acid chosen from arginine, glycine, proline, methionine, serine, lysine, histidine, salts thereof, or combinations of two or more thereof.

1 1 . The method of any one of claims 1 to 10, wherein the total amount of amino acids and salts thereof present in the treatment composition ranges from about 2% to about 15%, preferably from about 2.5% to about 12%, more preferably from about 3% to about 10%, most preferably from about 3.5% to about 8% by weight, relative to the total weight of the composition.

12. The method of any one of claims 1 to 1 1 , wherein the treatment composition comprises at least one carboxylic acid chosen from monocarboxylic acids, dicarboxylic acids, tricarboxylic acids, salts thereof, or combinations of two or more thereof.

13. The method of any one of claims 1 to 12, wherein the treatment composition comprises at least one carboxylic acid chosen from formic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, enanthic acid, caprylic acid, lactic acid, oxalic acid, malonic acid, malic acid, glutaric acid, citraconic acid, succinic acid, adipic acid, tartaric acid, fumaric acid, maleic acid, citric acid, isocitric acid, aconitic acid, propane-1 ,2,3-tricarboxylic acid, salts thereof, or combinations of two or more thereof.

14. The method of any one of claims 1 to 13, wherein the total amount of carboxylic acids and salts thereof present in the treatment composition ranges from about 3% to about 15%, preferably from about 3% to about 12%, more preferably from about 3.5% to about 10%, most preferably from about 4% to about 8% by weight, relative to the total weight of the composition.

15. The method of any one of claims 1 to 14, wherein the treatment composition further comprises at least one additional component chosen from fatty compounds, surfactants, thickening agents, or combinations of two or more thereof.

16. The method of any one of claims 1 to 15, wherein the treatment composition comprises: a) at least basic amino acid or salt thereof; b) at least one compound of formula (II) or a salt thereof; and c) at least one carboxylic acid or salt thereof.

17. The method of any one of claims 1 to 16, wherein the treatment composition comprises: a) at least one compound chosen from arginine or salts thereof; b) glycine betaine or a salt thereof; and c) at least one compound chosen from citric acid, lactic acid, or salts thereof.

18. The method of any one of claims 1 to 17, wherein the hair dye composition comprises at least one oxidation base chosen from paraphenylenediamines, bis(phenyl)alkylenediamines, para-aminophenols, ortho- aminophenols and heterocyclic bases, salts thereof, or combinations of two or more thereof.

19. The method of any one of claims 1 to 18, wherein the hair dye composition comprises at least one coupler compound.

20. The method of any one of claims 1 to 19, wherein step (i) occurs before step (ii), and the hair is optionally rinsed after step (i) and before step (ii).

21 . The method of any one of claims 1 to 19, wherein step (ii) occurs before step (i), and the hair is optionally rinsed after step (ii) and before step (i).

22. A method for treating keratin fibers, the method comprising:

(i) applying to the keratin fibers a treatment composition comprising: a) at least one compound chosen from basic amino acids or salts thereof; b) at least one osmolyte chosen from compounds of formula (II) or salts thereof:

(R1 )(R2)(R3)m-A⁺-CR4R5-(X)_n-Y-

(H) wherein:

R1 , R2, and R3 are independently chosen from C1 -C4 alkyl groups;

A is N or S; m and n are independently 0 or 1 ;

Y’ is -COO- or -OSO3-; with the provisos that: o when A is S, then m = 0 and R4 and R5 are independently chosen from a hydrogen atom or a saturated, unsaturated, linear, branched and/or cyclic (including aromatic and polycyclic chains), (C1 -C10) hydrocarbon chain, optionally interrupted by one or more heteroatoms or groups chosen from -S-, -N=, -NH-, or - C(NH)-, and/or optionally substituted by one or more groups chosen from hydroxyl (-OH), amino (-NH2), -SH, -COOH, or -CONH2; o when A is N and m = 0, R4 represents a hydrogen atom or a saturated, linear, or branched (C1 -C8)alkyl, and R5 forms, together with the nitrogen atom, a saturated heterocycle comprising from 5 to 8 ring members, optionally substituted by one or more groups chosen from hydroxyl or (C1 -C4)alkyl; and o when A is N and m = 1 , then R4 and R5 are independently chosen from a hydrogen atom or a saturated, unsaturated, linear, branched and/or cyclic (including aromatic and polycyclic chains) (C1 -C10) hydrocarbon chain, optionally interrupted by one or more heteroatoms or groups chosen from -S-, -N=, -NH-, or - C(NH)-, and/or optionally substituted by one or more groups chosen from hydroxyl (-OH), amino (-NH₂), -SH, -COOH, or -CONH₂; c) at least one compound chosen from carboxylic acids or salts thereof; and d) water and optionally at least one polyol, wherein the pH of the composition ranges from about 2 to about 6, wherein the total amount of basic amino acids and salts thereof ranges from about 2% to about 15% by weight, relative to the total weight of the composition, and wherein the total amount of carboxylic acids and salts thereof ranges from about 3% to about 15% by weight, relative to the total weight of the composition, and

23. The method of claim 22, wherein the treatment composition comprises at least one compound of formula (II) wherein:

R1 , R2, and R3 are methyl;

A is N;

Y is COO-;

X is a divalent alkyl group, linear or branched, preferably saturated, having from 1 to 4 carbon atoms, optionally substituted by methylene or ethylene;

R4 is hydrogen; and

R5 forms, together with the nitrogen atom, a saturated heterocycle comprising from 5 to 8 ring members, preferably 5 to 6 ring members, optionally substituted by one hydroxy group.

24. The method of claim 22 or claim 23, wherein the compounds of formula (II) are chosen from valine betaine, glutamic acid betaine, glutamine betaine, trimethyl lysine, glycine betaine, histidine betaine, N-methyl histidine betaine, alanine betaine, beta-alanine betaine, choline sulfate, pipecolic acid betaine, proline betaine, hydroxyproline betaine, tyrosine betaine, phenylalanine betaine, tryptophan betaine, leucine betaine, isoleucine betaine, salts thereof, or combinations of two or more thereof, preferably comprising glycine betaine.

25. The method of any one of claims 22 to 24, wherein the total amount of osmolytes present in the treatment composition ranges from about 0.5% to about 10%, preferably from about 1 % to about 8%, more preferably from about 1 % to about 5%, most preferably from about 1 .5% to about 3.5% by weight, relative to the total weight of the composition.

26. The method of any one of claims 22 to 25, wherein the treatment composition comprises at least one amino acid chosen from arginine, glycine, proline, methionine, serine, lysine, histidine, salts thereof, or combinations of two or more thereof, preferably comprising arginine.

27. The method of any one of claims 22 to 26, wherein the treatment composition comprises at least one carboxylic acid chosen from formic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, enanthic acid, caprylic acid, lactic acid, oxalic acid, malonic acid, malic acid, glutaric acid, citraconic acid, succinic acid, adipic acid, tartaric acid, fumaric acid, maleic acid, citric acid, isocitric acid, aconitic acid, propane-1 ,2,3-tricarboxylic acid, salts thereof, or combinations of two or more thereof.

28. The method of any one of claims 22 to 27, wherein the pH of the treatment composition ranges from about 2.5 to about 5.5, preferably from about 2.5 to about 5, more preferably from about 2.5 to about 4.5, most preferably from about 3 to about 4.

29. The method of any one of claims 22 to 28, wherein the hair dye composition comprises at least one oxidation base chosen from paraphenylenediamines, bis(phenyl)alkylenediamines, para-aminophenols, orthoaminophenols and heterocyclic bases, salts thereof, or combinations of two or more thereof.

30. The method of any one of claims 22 to 29, wherein the hair dye composition comprises at least one coupler compound.

31 . The method of any one of claims 22 to 30, wherein step (i) occurs before step (ii), and the hair is optionally rinsed after step (i) and before step (ii).

32. The method of any one of claims 22 to 30, wherein step (ii) occurs before step (i), and the hair is optionally rinsed after step (ii) and before step (i).

33. A method according to any one of claims 1 to 32, which is a method for providing strength to keratin fibers and/or for reducing elasticity of keratin fibers in a process for dyeing the keratin fibers.

34. A method according to any one of claims 1 to 33, which is a method for protecting keratin fibers in a process for dyeing the keratin fibers.